Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 8
1995 4
1996 11
1997 32
1998 26
1999 32
2000 31
2001 60
2002 58
2003 49
2004 87
2005 108
2006 139
2007 133
2008 144
2009 181
2010 207
2011 257
2012 266
2013 292
2014 294
2015 346
2016 317
2017 322
2018 349
2019 365
2020 384
2021 403
2022 383
2023 348
2024 337
2025 76

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,489 results

Results by year

Filters applied: Free full text. Clear all
Page 1
Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies.
Wawruszak A, Luszczki J, Bartuzi D, Kalafut J, Okon E, Czerwonka A, Stepulak A. Wawruszak A, et al. J Enzyme Inhib Med Chem. 2025 Dec;40(1):2458554. doi: 10.1080/14756366.2025.2458554. Epub 2025 Feb 12. J Enzyme Inhib Med Chem. 2025. PMID: 39935420 Free PMC article.
Sirtuins (SIRTs) are NAD+-dependent histone deacetylases, which play a key role in cancer progression; however, their prognostic values in breast cancer (BC) remain a subject of debate and controversy. ...To summarise, the combination of EX527 and PAX more ef …
Sirtuins (SIRTs) are NAD+-dependent histone deacetylases, which play a key role in cancer progression; however, their prognostic valu …
Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study.
Passildas J, Paillard MJ, Uwer L, Molnar I, Dohollou N, Petit T, Hajjaji N, Boudin L, Lorgis V, Jacquin JP, Abrial C, Mouret-Reynier MA. Passildas J, et al. Cancer Epidemiol. 2025 Mar 15;96:102800. doi: 10.1016/j.canep.2025.102800. Online ahead of print. Cancer Epidemiol. 2025. PMID: 40090228 Free article.
BACKGROUND: Eribulin can represent a therapeutic alternative for patients with advanced breast cancer who have received at least one or two lines of anthracyclines-based chemotherapy and taxane therapy. In this observational study, we focused on long-responde …
BACKGROUND: Eribulin can represent a therapeutic alternative for patients with advanced breast cancer who have received at lea …
A randomized trial of early cardiotoxicity in breast cancer patients receiving postoperative IMRT with or without serial cardiac dose constraints.
Cao L, Ou D, Qi WX, Xu C, Ye M, Fang YH, Shi M, Huang XB, Lin Q, Liu T, Cai G, Cai R, Chen M, Zhang YB, Su XX, Qian XF, Shen KW, Chen JY. Cao L, et al. Int J Cancer. 2025 Mar 15;156(6):1213-1224. doi: 10.1002/ijc.35245. Epub 2024 Nov 5. Int J Cancer. 2025. PMID: 39499199 Free PMC article. Clinical Trial.
Optimal cardiac dose constraints in breast cancer (BC) patients undergoing postoperative intensity-modulated radiation therapy (IMRT) are unclear, although as low as possible is recommended. ...Postoperative BC patients eligible for anthracycline/taxanes-base …
Optimal cardiac dose constraints in breast cancer (BC) patients undergoing postoperative intensity-modulated radiation therapy …
Short-term mortality in older (70 years) patients with early breast cancer treated with neo-/adjuvant chemotherapy: A Swedish nationwide retrospective population-based study.
Lundgren C, Engvall K, Fredriksson I, Valachis A. Lundgren C, et al. J Geriatr Oncol. 2025 Mar 13;16(3):102220. doi: 10.1016/j.jgo.2025.102220. Online ahead of print. J Geriatr Oncol. 2025. PMID: 40086025 Free article.
The aim of this study was to explore the impact of treatment setting (neoadjuvant vs. adjuvant) and different chemotherapeutic agents on short-term mortality among older patients with early breast cancer. MATERIAL AND METHODS: The population-based, national, researc …
The aim of this study was to explore the impact of treatment setting (neoadjuvant vs. adjuvant) and different chemotherapeutic agents on sho …
Prognostic role of STMN1 expression and neoadjuvant therapy efficacy in breast cancer.
Qian L, Cairong Z, Yongdong L, Quan L, Haihu Z, Xiaofeng Z, Xuan Y, Yongcheng C, Kai C, Guanming L, Jie L. Qian L, et al. BMC Cancer. 2025 Mar 13;25(1):453. doi: 10.1186/s12885-025-13798-6. BMC Cancer. 2025. PMID: 40082837 Free PMC article.
PURPOSE: breast cancer is common and highly malignant, currently, STMN1 was found to be associated with several human malignancies. ...CONCLUSIONS: STMN1 is the potential biomarker of NACT and prognosis for breast cancer....
PURPOSE: breast cancer is common and highly malignant, currently, STMN1 was found to be associated with several human malignan …
Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer.
Zhang Y, Chen H, Mo H, Zhao N, Sun X, Liu B, Gao R, Xu B, Zhang Z, Liu Z, Ma F. Zhang Y, et al. Cancer Cell. 2025 Mar 10;43(3):446-463.e7. doi: 10.1016/j.ccell.2025.01.007. Epub 2025 Feb 6. Cancer Cell. 2025. PMID: 39919737 Free article.
Combining immune checkpoint blockade (ICB) with chemotherapy shows promise for treating triple-negative breast cancer (TNBC), though the mechanisms remain incompletely understood. Here, we integrate published and new single-cell RNA sequencing (scRNA-seq) data to in …
Combining immune checkpoint blockade (ICB) with chemotherapy shows promise for treating triple-negative breast cancer (TNBC), …
Relationship between BMI and chemotherapy-induced peripheral neuropathy in cancer patients: a dose-response meta-analysis.
Yanbing L, Zijun L, Hongbo Z, Zhi W. Yanbing L, et al. World J Surg Oncol. 2025 Mar 8;23(1):77. doi: 10.1186/s12957-025-03716-2. World J Surg Oncol. 2025. PMID: 40055767 Free PMC article.
OBJECTIVE: This meta-analysis aimed to evaluate the dose-response relationship between body mass index (BMI) and the risk of chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients. METHODS: We conducted a dose-response meta-analysis of 10 studies involving 6, …
OBJECTIVE: This meta-analysis aimed to evaluate the dose-response relationship between body mass index (BMI) and the risk of chemotherapy-in …
Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: a meta-analysis.
Wu J, Wang Z, Fu Y. Wu J, et al. BMC Womens Health. 2025 Mar 7;25(1):104. doi: 10.1186/s12905-025-03628-z. BMC Womens Health. 2025. PMID: 40055784 Free PMC article.
BACKGROUND: This study aimed to evaluate the efficacy and safety of docetaxel plus capecitabine (TX) and docetaxel plus epirubicin (TE) in the treatment of human epidermal growth factor 2 (HER2)-negative breast cancer. METHODS: Relevant studies assessing the efficac …
BACKGROUND: This study aimed to evaluate the efficacy and safety of docetaxel plus capecitabine (TX) and docetaxel plus epirubicin (TE) in t …
Real World Evidence on Hormone Receptor Positive and Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer in Italy: Insights From 2017 to 2021 Data.
Perrone V, Leogrande M, Cappuccilli M, Saragoni S, Cinti Luciani A, Degli Esposti L. Perrone V, et al. Clinicoecon Outcomes Res. 2025 Mar 6;17:147-155. doi: 10.2147/CEOR.S496606. eCollection 2025. Clinicoecon Outcomes Res. 2025. PMID: 40066280 Free PMC article.
PURPOSE: To describe patients with hormone receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer (HR+/HER2- mBC) in Italy for demographic and clinical variables, comorbidity profile, metastases and therapeutic pathways. ... …
PURPOSE: To describe patients with hormone receptor positive and human epidermal growth factor receptor 2 negative metastatic breast …
Dual Anti-HER2 Therapy Vs Trastuzumab Alone with Neoadjuvant Anthracycline and Taxane in HER2-Positive Early-Stage Breast Cancer: Real-World Insights.
Sharaf B, Tamimi F, Al-Abdallat H, Khater S, Salama O, Zayed A, El Khatib O, Qaddoumi A, Horani M, Al-Masri Y, Asha W, Altalla' B, Bani Hani H, Abdel-Razeq H. Sharaf B, et al. Biologics. 2025 Mar 5;19:59-71. doi: 10.2147/BTT.S468650. eCollection 2025. Biologics. 2025. PMID: 40066239 Free PMC article.
INTRODUCTION: The integration of anti-HER2 targeted therapy with chemotherapy has demonstrated an increase in pathologic complete response rates (pCR) in patients with HER2-positive early-stage breast cancer (EBC). This study presents real-world data on the use of t …
INTRODUCTION: The integration of anti-HER2 targeted therapy with chemotherapy has demonstrated an increase in pathologic complete response r …
Fingerprint change as a consequence of anticancer treatments: A systematic integrative review.
Belloni S, Magon A, de Sanctis R, Tiberio P, Conte G, Arrigoni C, Caruso R. Belloni S, et al. Semin Oncol. 2025 Mar 3;52(1):41-54. doi: 10.1016/j.seminoncol.2025.152335. Online ahead of print. Semin Oncol. 2025. PMID: 40037149 Free article. Review.
Thus, we aimed to analyze the extent of evidence between cancer treatments and fingerprint alterations in adults with cancer. METHODS: A systematic integrative review was conducted according to the PRISMA statement and the Cochrane guidelines for conducting a system …
Thus, we aimed to analyze the extent of evidence between cancer treatments and fingerprint alterations in adults with cancer. …
Exploration of the role of drug resistance-associated anoikis-related genes in HER2-Negative breast cancer through bioinformatics analysis.
Wu Y, Chen C, Jin Z, Zheng K. Wu Y, et al. Biochem Biophys Rep. 2025 Feb 21;41:101947. doi: 10.1016/j.bbrep.2025.101947. eCollection 2025 Mar. Biochem Biophys Rep. 2025. PMID: 40065765 Free PMC article.
AIMS: To explore the potential functions and impacts of anoikis-related genes (ARGs) in breast cancer chemotherapy and to construct a prognosis model for HER2-negative breast cancer (HNBC) based on drug resistance-related ARGs. BACKGROUND: Breast …
AIMS: To explore the potential functions and impacts of anoikis-related genes (ARGs) in breast cancer chemotherapy and to cons …
Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.
Hotta K, Saeki S, Sakata S, Yamaguchi M, Harada D, Bessho A, Tanaka K, Inoue K, Inoue K, Gemba K, Kubo T, Sato A, Ichihara E, Watanabe H, Kishimoto J, Shioyama Y, Katsui K, Sugio K, Kiura K. Hotta K, et al. Int J Clin Oncol. 2025 Mar;30(3):497-503. doi: 10.1007/s10147-025-02696-3. Epub 2025 Feb 5. Int J Clin Oncol. 2025. PMID: 39910007 Free PMC article. Clinical Trial.
BACKGROUND: We previously showed the 2-year OS rate, the primary endpoint, of 90% in a phase II trial of gefitinib induction followed by chemoradiotherapy (CRT) in unresectable, stage III, EGFR-mutant, non-small-cell lung cancer (NSCLC). However, neither long-term survival …
BACKGROUND: We previously showed the 2-year OS rate, the primary endpoint, of 90% in a phase II trial of gefitinib induction followed by che …
Clavulanic acid prevents paclitaxel-induced neuropathic pain through a systemic and central anti-inflammatory effect in mice.
Balcazar-Ochoa LG, Ángeles-López GE, Chavarría A, Ramírez-Carreto RJ, González-Hernández A, Guzmán-Ruiz MA, Segovia-Mendoza M, Ochoa-Aguilar A, Ventura-Martínez R. Balcazar-Ochoa LG, et al. Neurotherapeutics. 2025 Mar;22(2):e00522. doi: 10.1016/j.neurot.2024.e00522. Epub 2025 Jan 9. Neurotherapeutics. 2025. PMID: 39794241 Free article.
Paclitaxel (PCX) based treatments, commonly used to treat breast, ovarian and lung cancers, have the highest incidence of chemotherapy-induced neuropathic pain, affecting from 38 to 94 % of patients. ...Notably, co-incubation with CLAV and PCX in triple-negative breast …
Paclitaxel (PCX) based treatments, commonly used to treat breast, ovarian and lung cancers, have the highest incidence of chemotherap …
Inhibition of XIST restrains paclitaxel resistance in breast cancer cells by targeting hsa-let-7d-5p/ATG16L1 through regulation of autophagy.
Wang Y, Pei W, Yang Y, Xia C, Zhang Q, Geng Z, Shi X, Wang F. Wang Y, et al. Cell Signal. 2025 Mar;127:111534. doi: 10.1016/j.cellsig.2024.111534. Epub 2024 Dec 3. Cell Signal. 2025. PMID: 39638138 Free article.
This study aimed to investigate the function of long non-coding RNA (lncRNA) in breast cancer cell chemoresistance and autophagy. The paclitaxel (PTX)-resistant breast cancer cells were established. ...Our results verified that XIST played a significan …
This study aimed to investigate the function of long non-coding RNA (lncRNA) in breast cancer cell chemoresistance and autopha …
Comparative study of dexamethasone premedication regimens with docetaxel chemotherapy in early HER-2 positive breast cancer: A safety net hospital experience.
Hager A, Kondle S, Agarwal A, Chintapenta M, Horadam R, Sadeghi N, Syed S. Hager A, et al. J Oncol Pharm Pract. 2025 Mar;31(2):236-244. doi: 10.1177/10781552241232692. Epub 2024 Feb 29. J Oncol Pharm Pract. 2025. PMID: 38425269 Free PMC article.
We also examined side effects of dexamethasone and delays in chemotherapy.MethodsA retrospective chart review was conducted on 82 early breast cancer patients treated with docetaxel. Three steroid regimens were examined: IV 20 mg single-dose dexamethasone, or IV 12 …
We also examined side effects of dexamethasone and delays in chemotherapy.MethodsA retrospective chart review was conducted on 82 early b …
A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC).
Arora A, Seenu V, Parshad R, Bansal VK, Dhar A, Mathur S, Tanwar P, Mishra P, Kataria K, Suhani, Gogia A, Kumar B, Haresh KP, Mallick S, Saini SK, Mishra A, Bansal B, Sharma J, Saikia J, Rangarajan K, Dhamija E, Prasad CP, Shamin SA, Agastm S, Kalra K, Vishvam D, Mani K, Kumar A, Bakhshi S, Batra A. Arora A, et al. Trials. 2025 Feb 27;26(1):73. doi: 10.1186/s13063-025-08726-9. Trials. 2025. PMID: 40011935 Free PMC article. Clinical Trial.
BACKGROUND: Breast cancer is the most common malignancy diagnosed in women worldwide. Triple-negative breast cancer (TNBC) is the most aggressive subtype, accounting for nearly one third of all breast cancers in India. ...DISCUSSION: The PLANeT …
BACKGROUND: Breast cancer is the most common malignancy diagnosed in women worldwide. Triple-negative breast cancer …
Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial.
Dennis N, Dunton K, Livings C, Bogoeva N, Bourke S, Oluboyede Y, Hamilton E, Iwata H, Cortés J. Dennis N, et al. Eur J Cancer. 2025 Feb 25;217:115192. doi: 10.1016/j.ejca.2024.115192. Epub 2024 Dec 26. Eur J Cancer. 2025. PMID: 39798264 Free article. Clinical Trial.
OBJECTIVE: DESTINY-Breast03, a randomised, phase 3 trial, evaluated trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor (HER2)-positive unresectable and/or metastatic breast cancer who progresse …
OBJECTIVE: DESTINY-Breast03, a randomised, phase 3 trial, evaluated trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in p …
MF59-based lipid nanocarriers for paclitaxel delivery: optimization and anticancer evaluation.
Attar M, Tash Shamsabadi F, Soltani A, Joghataei MT, Khandoozi SR, Teimourian S, Shahbazi M, Erfani-Moghadam V. Attar M, et al. Sci Rep. 2025 Feb 24;15(1):6583. doi: 10.1038/s41598-025-91504-z. Sci Rep. 2025. PMID: 39994380 Free PMC article.
Breast cancer is the most common invasive cancer in women worldwide, necessitating innovative therapeutic strategies to enhance treatment efficacy and safety. ...In vitro cytotoxicity assays demonstrated that these MF59-based NLCs effectively target MCF-7 (Mi …
Breast cancer is the most common invasive cancer in women worldwide, necessitating innovative therapeutic strategies to …
Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review.
Ventura I, Salcedo NP, Pérez-Bermejo M, Pérez-Murillo J, Tejeda-Adell M, Tomás-Aguirre F, Legidos-García ME, Murillo-Llorente MT. Ventura I, et al. Int J Mol Sci. 2025 Feb 23;26(5):1908. doi: 10.3390/ijms26051908. Int J Mol Sci. 2025. PMID: 40076535 Free PMC article. Review.
Breast cancer is the most clinically relevant pathology of the mammary gland and is currently the most diagnosed malignant disease among women worldwide. In breast cancer prevention, it is important to consider that the risk of developing the disease i …
Breast cancer is the most clinically relevant pathology of the mammary gland and is currently the most diagnosed malignant dis …
Use of medications in women with triple-negative breast cancer between 2018 and 2019 in a Brazilian public hospital: a retrospective study.
Pires MCDS, Sobreira-da-Silva MJ, Araújo PP, Retto MPF. Pires MCDS, et al. Epidemiol Serv Saude. 2025 Feb 21;34:e20240180. doi: 10.1590/S2237-96222025v34e20240180.en. eCollection 2025. Epidemiol Serv Saude. 2025. PMID: 40008715 Free PMC article.
OBJECTIVE: To describe the profile of medication use in women with triple-negative breast cancer treated between 2018 and 2019 in a Brazilian public hospital. METHODS: Descriptive and retrospective study, with data obtained from the Hospital Cancer Registry a …
OBJECTIVE: To describe the profile of medication use in women with triple-negative breast cancer treated between 2018 and 2019 …
Docetaxel rechallenge in HER2-negative metastatic breast cancer: a real-world study of previously discontinued patients for non-progression reasons.
Zeng HA, Lv HM, Zhang MW, Niu LM, Wang J, Sun HH, Liu ZZ, Yan M. Zeng HA, et al. J Cancer Res Clin Oncol. 2025 Feb 21;151(2):89. doi: 10.1007/s00432-025-06133-w. J Cancer Res Clin Oncol. 2025. PMID: 39979499 Free PMC article.
PURPOSE: This study aimed to evaluate the efficacy and safety of docetaxel rechallenge in HER2-negative metastatic breast cancer (MBC) patients who discontinued docetaxel for reasons other than disease progression. ...
PURPOSE: This study aimed to evaluate the efficacy and safety of docetaxel rechallenge in HER2-negative metastatic breast cancer …
The impact of functional MDM2-polymorphisms on neutrophil counts in breast cancer patients during neoadjuvant chemotherapy.
Hatletvedt ND, Engebrethsen C, Geisler J, Geisler S, Aas T, Lønning PE, Gansmo LB, Knappskog S. Hatletvedt ND, et al. BMC Cancer. 2025 Feb 20;25(1):308. doi: 10.1186/s12885-025-13675-2. BMC Cancer. 2025. PMID: 39979836 Free PMC article.
METHODS: We investigated the potential associations between genotypes of MDM2 SNP309 (rs2279744), SNP285 (rs117039649) and del1518 (rs3730485) and neutrophil counts in breast cancer patients receiving neoadjuvant sequential epirubicin and docetaxel, with additional …
METHODS: We investigated the potential associations between genotypes of MDM2 SNP309 (rs2279744), SNP285 (rs117039649) and del1518 (rs373048 …
Advancing triple-negative breast cancer treatment through peptide decorated solid lipid nanoparticles for paclitaxel delivery.
Rahdari T, Mahdavimehr M, Ghafouri H, Ramezanpour S, Ehtesham S, Asghari SM. Rahdari T, et al. Sci Rep. 2025 Feb 19;15(1):6043. doi: 10.1038/s41598-025-90107-y. Sci Rep. 2025. PMID: 39972039 Free PMC article.
Triple-negative breast cancer (TNBC) presents a global health challenge due to its aggressive behavior and limited treatment options. ...These findings highlight the potential of C-peptide-SLNs as an effective targeted PTX delivery system for TNBC, offering promisin …
Triple-negative breast cancer (TNBC) presents a global health challenge due to its aggressive behavior and limited treatment o …
Chronic chemotherapy-induced peripheral neuropathy and pain following paclitaxel versus docetaxel in breast cancer survivors: A cross-sectional study.
Gehr NL, Timm S, Bennedsgaard K, Grosen K, Jakobsen E, Jensen AB, Rønlev JD, Knoop AS, Finnerup NB, Ventzel L. Gehr NL, et al. Breast. 2025 Feb 16;80:104424. doi: 10.1016/j.breast.2025.104424. Online ahead of print. Breast. 2025. PMID: 39978151 Free PMC article.
Patients with breast cancer who had followed Danish recommended adjuvant docetaxel or paclitaxel treatment regimens completed an online questionnaire 2-3 years after treatment. ...These findings are highly relevant, as docetaxel remains a crucial component of can …
Patients with breast cancer who had followed Danish recommended adjuvant docetaxel or paclitaxel treatment regimens completed …
Reassessing regional nodal radiotherapy strategies for breast cancer in the context of modern systemic treatments.
Yang WC, Chen YH, Lai SF, Wang CC, Kuo SH, Huang CS. Yang WC, et al. J Formos Med Assoc. 2025 Feb 15:S0929-6646(25)00057-9. doi: 10.1016/j.jfma.2025.02.015. Online ahead of print. J Formos Med Assoc. 2025. PMID: 39956679 Free article.
BACKGROUND: The efficacy of radiotherapy to the internal mammary node (IMN-RT) and axillary lymph node regions (ALRT) in enhancing disease-free survival (DFS) among patients with breast cancer (BC) in the context of contemporary systemic chemotherapy has not been cl …
BACKGROUND: The efficacy of radiotherapy to the internal mammary node (IMN-RT) and axillary lymph node regions (ALRT) in enhancing disease-f …
Computational development of mushroom-6-glucan/paclitaxel as a synergistic complementary medicine for breast cancer therapy.
El-Deeb NM, Ibrahim OM, Kamel AM, Gomaa AI, Kenawy AM. El-Deeb NM, et al. BMC Complement Med Ther. 2025 Feb 15;25(1):58. doi: 10.1186/s12906-025-04772-7. BMC Complement Med Ther. 2025. PMID: 39955575 Free PMC article.
BACKGROUND: Breast cancer is chemo-resistant and highly metastatic, often resulting in patient mortality. ...METHODS: We computationally developed a specific dual combinatorial therapy involving 6-glucans and Paclitaxel (PTX) and tested on preclinical 3D mammosphere …
BACKGROUND: Breast cancer is chemo-resistant and highly metastatic, often resulting in patient mortality. ...METHODS: We compu …
Small Molecules Identified by an In Silico Docking Screen Targeting Anaphase-Promoting Complex/Cyclosome Subunit 1 (APC1) Potentiate Paclitaxel-Induced Breast Cancer Cell Death.
Schuyler SC, Gupta R, Nguyen TTB, Weng CY, Chen HY. Schuyler SC, et al. Molecules. 2025 Feb 14;30(4):895. doi: 10.3390/molecules30040895. Molecules. 2025. PMID: 40005207 Free PMC article.
As a secondary in cellulo bioactivity screening, MDA-MB-231 genomically unstable aneuploid breast cancer cells were exposed to each compound in the absence and presence of 10 nM paclitaxel or 1 nM eribulin, the likely clinically relevant doses of these drugs in thes …
As a secondary in cellulo bioactivity screening, MDA-MB-231 genomically unstable aneuploid breast cancer cells were exposed to …
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial.
Dieci MV, Bisagni G, Bartolini S, Schirone A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Sarti S, Ferro A, Piacentini F, Orvieto E, Sanders M, Miglietta F, Massa D, Balduzzi S, Conte P, D'Amico R, Guarneri V. Dieci MV, et al. JAMA Oncol. 2025 Feb 13:e246872. doi: 10.1001/jamaoncol.2024.6872. Online ahead of print. JAMA Oncol. 2025. PMID: 39946142 Free PMC article.
IMPORTANCE: For patients with early ERBB2 (formerly HER2)-positive breast cancer, there is a need to identify biomarkers to guide treatment de-escalation. OBJECTIVE: To evaluate the association of tumor-infiltrating lymphocytes (TILs) with distant disease-free (DDFS …
IMPORTANCE: For patients with early ERBB2 (formerly HER2)-positive breast cancer, there is a need to identify biomarkers to gu …
Addition of Bevacizumab to Vinorelbine-Platinum combination is efficacious in Heavily Pretreated HER2-Negative Metastatic Breast Cancer.
Ho IW, Tseng YR, Liu CY, Tsai YF, Huang CC, Tseng LM, Chao TC, Lai JI. Ho IW, et al. J Cancer. 2025 Feb 11;16(5):1726-1735. doi: 10.7150/jca.105199. eCollection 2025. J Cancer. 2025. PMID: 39991566 Free PMC article.
Introduction: Despite rapidly improving therapeutics, challenges remain in the treatment of advanced breast cancer. Vinorelbine, a semisynthetic vinca alkaloid, is effective and well-tolerated in breast cancer treatment. ...To model the molecular pertu …
Introduction: Despite rapidly improving therapeutics, challenges remain in the treatment of advanced breast cancer. Vinorelbin …
Modeling and estimation of physiochemical properties of cancer drugs using entropy measures.
Tawhari QM, Naeem M, Rauf A, Siddiqui MK, Oyelakin O. Tawhari QM, et al. Sci Rep. 2025 Feb 8;15(1):4785. doi: 10.1038/s41598-025-87755-5. Sci Rep. 2025. PMID: 39922858 Free PMC article.
This conjugate shows promise in treating breast, lung, and ovarian cancers with reduced side effects. Entropy measures are used to predict physical and chemical properties of drugs. ...We establish a quantitative structure-property relationship using reverse entropy measur …
This conjugate shows promise in treating breast, lung, and ovarian cancers with reduced side effects. Entropy measures are used to pr …
Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial.
Shen G, Liu Z, Wang M, Zhao Y, Liu X, Hou Y, Ma W, Han J, Zhou X, Ren D, Zhao F, Li Z, Huang S, Chen Y, He Y, Liu Y, Zhu Z, Li Y, Li J, Da M, Mo H, Du F, Cui L, Bai J, Liu Z, Ma F, Zhao J. Shen G, et al. Signal Transduct Target Ther. 2025 Feb 7;10(1):41. doi: 10.1038/s41392-025-02137-7. Signal Transduct Target Ther. 2025. PMID: 39915443 Free PMC article. Clinical Trial.
We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative breast cancer (TNBC). In the phase 2 NeoSAC trial, patients with early TNBC received six cycles of apatinib, sintili …
We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple …
TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.
Calistri NL, Liby TA, Hu Z, Zhang H, Dane MA, Gross SM, Heiser LM. Calistri NL, et al. Sci Rep. 2025 Feb 4;15(1):4294. doi: 10.1038/s41598-024-82218-9. Sci Rep. 2025. PMID: 39905117 Free PMC article.
Paclitaxel is a standard of care neoadjuvant therapy for patients with triple negative breast cancer (TNBC); however, it shows limited benefit for locally advanced or metastatic disease. ...We found that ELF3 knockdown synergized with paclitaxel treatment to lock ce …
Paclitaxel is a standard of care neoadjuvant therapy for patients with triple negative breast cancer (TNBC); however, it shows …
Structural Dynamics of OATP1A2 in Mediating Paclitaxel Transport Mechanism in Breast Cancer.
Kumar R, Singh G, Akhter Y, Kaithwas G, Agrawal AK, Singh S. Kumar R, et al. Nanotheranostics. 2025 Feb 3;9(1):52-62. doi: 10.7150/ntno.103095. eCollection 2025. Nanotheranostics. 2025. PMID: 40078312 Free PMC article.
Breast cancer remains a significant global health challenge, with drug resistance and poor bioavailability of chemotherapeutic agents like paclitaxel (PTX) presenting obstacles to effective treatment. ...These results accentuate the complexity of transporter-mediate …
Breast cancer remains a significant global health challenge, with drug resistance and poor bioavailability of chemotherapeutic …
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Richters L, Gluz O, Weber-Lassalle N, Christgen M, Haverkamp H, Kuemmel S, Kayali M, Kates RE, Grischke EM, Altmüller J, Forstbauer H, Thiele H, Braun M, Warm M, Ossowski A, Wuerstlein R, Ernst C, Graeser M, Linn SC, Nitz U, Hauke J, Kreipe HH, Schmutzler RK, Hahnen E, Harbeck N. Richters L, et al. JAMA Netw Open. 2025 Feb 3;8(2):e2461639. doi: 10.1001/jamanetworkopen.2024.61639. JAMA Netw Open. 2025. PMID: 40009381 Free PMC article. Clinical Trial.
IMPORTANCE: Subgroup definitions for possible deescalation of neoadjuvant cancer treatment are urgently needed in clinical practice. OBJECTIVE: To investigate the effect of BRCA1 and/or BRCA2 tumor pathogenic variants (tPVs) by comparing 2 deescalated neoadjuvant regimens …
IMPORTANCE: Subgroup definitions for possible deescalation of neoadjuvant cancer treatment are urgently needed in clinical practice. …
Association between chemotherapy and the risk of developing breast cancer-related lymphedema: a nationwide retrospective cohort study.
Jeong SH, Chun SM, Lee H, Kim M, Choi M, Leigh JH. Jeong SH, et al. Support Care Cancer. 2025 Feb 3;33(2):143. doi: 10.1007/s00520-025-09169-3. Support Care Cancer. 2025. PMID: 39899036 Free PMC article.
PURPOSE: Breast cancer-related lymphedema (BCRL) is a well-known complication of breast cancer treatment, which often includes chemotherapy. ...CONCLUSION: Chemotherapy administration following a diagnosis of breast cancer increases the r …
PURPOSE: Breast cancer-related lymphedema (BCRL) is a well-known complication of breast cancer treatment, which …
Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial.
Guchelaar NAD, Mathijssen RHJ, de Boer M, van Bekkum ML, Heijns JB, Vriens BEPJ, van Rosmalen MM, Kessels LW, Hamming L, Beelen KJ, Nieboer P, van den Berg SM, Hoop EO, Bijlsma RM, Bos MEMM; Dutch Breast Cancer Research Group (BOOG). Guchelaar NAD, et al. EClinicalMedicine. 2025 Jan 27;80:103065. doi: 10.1016/j.eclinm.2024.103065. eCollection 2025 Feb. EClinicalMedicine. 2025. PMID: 40017682 Free PMC article.
BACKGROUND: Effective later-line chemotherapy treatment options are scarce for patients with metastatic breast cancer (MBC). Trifluridine-tipiracil has shown survival benefit in heavily pre-treated patients with metastatic colorectal and in gastric cancer ref …
BACKGROUND: Effective later-line chemotherapy treatment options are scarce for patients with metastatic breast cancer (MBC). T …
Plant-derived extracellular vesicles as nanocarriers for combination therapy enhancing paclitaxel-based regimens in breast cancer.
Song Y, Kong H, Oh S, Kim SB. Song Y, et al. BMB Rep. 2025 Feb;58(2):53-63. doi: 10.5483/BMBRep.2024-0193. BMB Rep. 2025. PMID: 39978779 Free PMC article. Review.
Breast cancer remains a leading cause of morbidity and mortality worldwide. Triple-negative breast cancer (TNBC) presents unique challenges owing to its aggressiveness and limited treatment options. Paclitaxel-based chemotherapy is widely used in br …
Breast cancer remains a leading cause of morbidity and mortality worldwide. Triple-negative breast cancer (TNBC) …
RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic-nuclear shuttling in human triple-negative breast cancer.
Huang S, Shi D, Dai S, Jiang X, Wang R, Yang M, Chen B, Chen X, Kong L, He L, Deng P, Chen X, Lin C, Li Y, Li J, Song L, Shi Y, Wei W. Huang S, et al. Clin Transl Med. 2025 Feb;15(2):e70203. doi: 10.1002/ctm2.70203. Clin Transl Med. 2025. PMID: 39915011 Free PMC article.
BACKGROUND: Resistance to paclitaxel-based chemotherapy is the major obstacle in triple-negative breast cancer (TNBC) treatment. However, overcoming paclitaxel resistance remains an unsolved problem. ...
BACKGROUND: Resistance to paclitaxel-based chemotherapy is the major obstacle in triple-negative breast cancer (TNBC) treatmen …
Efficacy and Safety of Low-Dose Oral Etoposide Combined With Capecitabine for Patients With Postoperative Metastatic Breast Cancer Resistant to Anthracycline/Taxanes.
Chen X, He Y, Fan T, Wei Y. Chen X, et al. Thorac Cancer. 2025 Feb;16(3):e70003. doi: 10.1111/1759-7714.70003. Thorac Cancer. 2025. PMID: 39901856 Free PMC article.
INTRODUCTION: The purpose of this study is to determine the efficacy and safety of metronomic chemotherapy with all-oral combination of low-dose etoposide/capecitabine in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and/or t …
INTRODUCTION: The purpose of this study is to determine the efficacy and safety of metronomic chemotherapy with all-oral combination of low- …
VEGFA Gene Expression in Breast Cancer Is Associated With Worse Prognosis, but Better Response to Chemotherapy and Immunotherapy.
Sharma P, Chida K, Wu R, Tung K, Hakamada K, Ishikawa T, Takabe K. Sharma P, et al. World J Oncol. 2025 Feb;16(1):120-130. doi: 10.14740/wjon1993. Epub 2025 Jan 13. World J Oncol. 2025. PMID: 39850522 Free PMC article.
Notably, Avastin, which targets VEGFA, failed to demonstrate any significant benefit in clinical trials for breast cancer (BC). This study aimed to investigate the clinical relevance of VEGFA gene expression in BC. METHODS: A total of 7,336 BC patients across eight …
Notably, Avastin, which targets VEGFA, failed to demonstrate any significant benefit in clinical trials for breast cancer (BC) …
One-year incidence of chemotherapy-induced peripheral neuropathy in oxaliplatin- or taxane-based chemotherapy: a multicenter, prospective registry study (MiroCIP study).
Misawa S, Denda T, Kodama S, Suzuki T, Naito Y, Kogawa T, Takada M, Hino A, Shiosakai K, Kuwabara S. Misawa S, et al. Expert Opin Pharmacother. 2025 Feb;26(3):335-344. doi: 10.1080/14656566.2025.2455445. Epub 2025 Feb 2. Expert Opin Pharmacother. 2025. PMID: 39840660 Free article.
RESEARCH DESIGN AND METHODS: This 1-year, multicenter, prospective registry study (May 2021-April 2023) included patients aged 20 years with colorectal, gastric, non-small cell lung, or breast cancer who were scheduled to undergo chemotherapy with oxaliplatin or …
RESEARCH DESIGN AND METHODS: This 1-year, multicenter, prospective registry study (May 2021-April 2023) included patients aged 20 years with …
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.
Loi S, Salgado R, Curigliano G, Romero Díaz RI, Delaloge S, Rojas García CI, Kok M, Saura C, Harbeck N, Mittendorf EA, Yardley DA, Suárez Zaizar A, Caminos FR, Ungureanu A, Reinoso-Toledo JG, Guarneri V, Egle D, Ades F, Pacius M, Chhibber A, Chandra R, Nathani R, Spires T, Wu JQ, Pusztai L, McArthur H. Loi S, et al. Nat Med. 2025 Feb;31(2):433-441. doi: 10.1038/s41591-024-03414-8. Epub 2025 Jan 21. Nat Med. 2025. PMID: 39838118 Free PMC article. Clinical Trial.
Patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC) have low pathological complete response (pCR) rates with neoadjuvant chemotherapy. ...In total, 510 patients were randomized to recei …
Patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer …
Internal mammary node irradiation in 4541 node-positive breast cancer patients treated with newer systemic therapies and 3D-based radiotherapy (DBCG IMN2): a prospective, nationwide, population-based cohort study.
Nielsen AWM, Thorsen LBJ, Özcan D, Matthiessen LW, Maae E, Milo MLH, Nielsen MH, Tramm T, Overgaard J, Offersen BV; DBCG RT Committee. Nielsen AWM, et al. Lancet Reg Health Eur. 2024 Dec 12;49:101160. doi: 10.1016/j.lanepe.2024.101160. eCollection 2025 Feb. Lancet Reg Health Eur. 2024. PMID: 39810969 Free PMC article.
Therefore, the Danish Breast Cancer Group (DBCG) IMN2 study aimed to investigate the effect of IMNI in node-positive breast cancer patients treated with newer systemic therapies and 3D-based RT. ...INTERPRETATION: IMNI reduced distant metastasis and …
Therefore, the Danish Breast Cancer Group (DBCG) IMN2 study aimed to investigate the effect of IMNI in node-positive breast …
UGCG promotes chemoresistance and breast cancer progression via NF-kappaB and Wnt/beta-catenin pathway activation.
Long L, Wang L, Liang Y, Ye F, Jin Y, Luo D, Li X, Wang Y, Li Y, Han D, Chen B, Zhao W, Wang L, Yang Q. Long L, et al. Transl Oncol. 2025 Feb;52:102241. doi: 10.1016/j.tranon.2024.102241. Epub 2024 Dec 13. Transl Oncol. 2025. PMID: 39674092 Free PMC article.
BACKGROUND: Taxane-based chemotherapy is the primary treatment for triple-negative breast cancer (TNBC), yet clinical outcomes remain unsatisfactory due to the persistence of chemoresistance. ...RESULTS: UGCG expression was notably elevated in chemoresistant …
BACKGROUND: Taxane-based chemotherapy is the primary treatment for triple-negative breast cancer (TNBC), yet clinical o …
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Rugo HS, Campbell M, Yau C, Jo Chien A, Wallace AM, Isaacs C, Boughey JC, Han HS, Buxton M, Clennell JL, Asare SM, Steeg K, Wilson A, Singhrao R, Matthews JB, Perlmutter J, Fraser Symmans W, Hylton NM, DeMichele AM, Yee D, Van't Veer LJ, Berry DA, Esserman LJ. Rugo HS, et al. Breast Cancer Res Treat. 2025 Feb;209(3):487-492. doi: 10.1007/s10549-024-07555-9. Epub 2024 Dec 3. Breast Cancer Res Treat. 2025. PMID: 39625569 Free PMC article. Clinical Trial.
The adaptive randomization engine preferentially assigns patients based upon cumulative performance of each agent in a given breast cancer subtype based on hormone receptor and HER2 receptor status. The study endpoint is pathologic complete response. ...CONCLUSION: …
The adaptive randomization engine preferentially assigns patients based upon cumulative performance of each agent in a given breast …
Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort.
Almekinders CAM, Lin L, Beijnen JH, Sonke GS, Huitema ADR, Dezentjé VO. Almekinders CAM, et al. Breast Cancer Res Treat. 2025 Feb;210(1):115-124. doi: 10.1007/s10549-024-07542-0. Epub 2024 Nov 7. Breast Cancer Res Treat. 2025. PMID: 39508972 Free PMC article.
PURPOSE: Palliative treatment options for HR + HER2- advanced breast cancer (ABC) patients have increased, but data is lacking about the optimal treatment sequence. We used real-world data from a comprehensive cancer center to describe applied treatment seque …
PURPOSE: Palliative treatment options for HR + HER2- advanced breast cancer (ABC) patients have increased, but data is lacking …
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.
Martín M, Stecklein SR, Gluz O, Villacampa G, Monte-Millán M, Nitz U, Cobo S, Christgen M, Brasó-Maristany F, Álvarez EL, Echavarría I, Conte B, Kuemmel S, Bueno-Muiño C, Jerez Y, Kates R, Cebollero M, Kolberg-Liedtke C, Bueno O, García-Saenz JÁ, Moreno F, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Wuerstleins R, Graeser M, Zu Eulenburg C, Kreipe HH, Gómez H, Massarrah T, Herrero B, Paré L, Bohn U, López-Tarruella S, Vivancos A, Sanfeliu E, Parker JS, Perou CM, Villagrasa P, Prat A, Sharma P, Harbeck N. Martín M, et al. Ann Oncol. 2025 Feb;36(2):158-171. doi: 10.1016/j.annonc.2024.10.012. Epub 2024 Oct 16. Ann Oncol. 2025. PMID: 39419289 Free article.
BACKGROUND: Identification of biomarkers to optimize treatment strategies for early-stage triple-negative breast cancer (TNBC) is crucial. This study presents the development and validation of TNBC-DX, a novel test aimed at predicting both short- and long-term outco …
BACKGROUND: Identification of biomarkers to optimize treatment strategies for early-stage triple-negative breast cancer (TNBC) …
ART26.12, a novel fatty acid-binding protein 5 inhibitor, shows efficacy in multiple preclinical neuropathy models.
Warren WG, Osborn M, David-Pereira A, Tsantoulas C, Xue W, Yates A, OSullivan SE. Warren WG, et al. Eur J Pain. 2025 Feb;29(2):e4718. doi: 10.1002/ejp.4718. Epub 2024 Aug 26. Eur J Pain. 2025. PMID: 39188040 Free PMC article.
BACKGROUND: Painful neuropathy is a pathological condition caused by numerous factors including diabetes, chemotherapy or cancer. ART26.12 is a novel fatty acid-binding protein 5 inhibitor, which our group showed could prevent and treat persistent pain in a preclinical mod …
BACKGROUND: Painful neuropathy is a pathological condition caused by numerous factors including diabetes, chemotherapy or cancer. ART …
The analysis of transcriptomic signature of TNBC-searching for the potential RNA-based predictive biomarkers to determine the chemotherapy sensitivity.
Supplitt S, Karpinski P, Sasiadek M, Laczmanski L, Kujawa D, Matkowski R, Kasprzak P, Abrahamowska M, Maciejczyk A, Iwaneczko E, Laczmanska I. Supplitt S, et al. J Appl Genet. 2025 Feb;66(1):171-182. doi: 10.1007/s13353-024-00876-x. Epub 2024 May 9. J Appl Genet. 2025. PMID: 38722458 Free PMC article.
Neoadjuvant chemotherapy is the foundation treatment for triple-negative breast cancer (TNBC) and frequently results in pathological complete response (pCR). However, there are large differences in clinical response and survival after neoadjuvant chemotherapy of TNB …
Neoadjuvant chemotherapy is the foundation treatment for triple-negative breast cancer (TNBC) and frequently results in pathol …
Effect of exercise before and/or during taxane-containing chemotherapy treatment on chemotherapy-induced peripheral neuropathy symptoms in women with breast cancer: systematic review and meta-analysis.
Brownson-Smith R, Orange ST, Cresti N, Hunt K, Saxton J, Temesi J. Brownson-Smith R, et al. J Cancer Surviv. 2025 Feb;19(1):78-96. doi: 10.1007/s11764-023-01450-w. Epub 2023 Aug 24. J Cancer Surviv. 2025. PMID: 37615928 Free PMC article. Review.
PURPOSE: To systematically review and meta-analyse the efficacy of exercise interventions delivered before and/or during taxane-containing chemotherapy regimens on chemotherapy-induced peripheral neuropathy (CIPN), fatigue, and health-related quality of life (HR-QoL), in w …
PURPOSE: To systematically review and meta-analyse the efficacy of exercise interventions delivered before and/or during taxane-conta …
Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study.
Schmidt M, Hesse T, Hoffmann O, Heinrich BJ, Park-Simon TW, Grischke EM, Weide R, Müller Huesmann H, Lüdtke-Heckenkamp K, Fischer D, Zemlin C, Kögel M, Jia Y, Schmitz H, Engelbrecht C, Jackisch C. Schmidt M, et al. Cancers (Basel). 2025 Jan 28;17(3):457. doi: 10.3390/cancers17030457. Cancers (Basel). 2025. PMID: 39941823 Free PMC article.
Eribulin is a preferred treatment for patients with advanced breast cancer (BC) following anthracyclines and taxanes. The final analysis of the IRENE study assessed the incidence and resolution of eribulin-induced peripheral neuropathy (EIPN), along with safe …
Eribulin is a preferred treatment for patients with advanced breast cancer (BC) following anthracyclines and taxanes. T …
CD44-Receptors-Mediated Multiprong Targeting Strategy Against Breast Cancer and Tumor-Associated Macrophages: Design, Optimization, Characterization, and Cytologic Evaluation.
Hussain Z, Abdulrahim Abdul Moti L, Jagal J, Thu HE, Khan S, Kazi M. Hussain Z, et al. Int J Nanomedicine. 2025 Jan 25;20:991-1020. doi: 10.2147/IJN.S480553. eCollection 2025. Int J Nanomedicine. 2025. PMID: 39881963 Free PMC article.
INTRODUCTION: Owing to its high prevalence, colossal potential of chemoresistance, metastasis, and relapse, breast cancer (BC) is the second leading cause of cancer-related fatalities in women. Several treatments (eg, chemotherapy, surgery, radiations, hormon …
INTRODUCTION: Owing to its high prevalence, colossal potential of chemoresistance, metastasis, and relapse, breast cancer (BC) …
Proteomic profiling identifies upregulation of aurora kinases causing resistance to taxane-type chemotherapy in triple negative breast cancer.
Ning B, Liu C, Kucukdagli AC, Zhang J, Jing H, Zhou Z, Zhang Y, Dong Y, Chen Y, Guo H, Xu J. Ning B, et al. Sci Rep. 2025 Jan 25;15(1):3211. doi: 10.1038/s41598-025-87315-x. Sci Rep. 2025. PMID: 39863788 Free PMC article.
Nowadays, chemotherapy and immunotherapy remain the major treatment strategies for Triple-Negative Breast Cancer (TNBC). Identifying biomarkers to pre-select and subclassify TNBC patients with distinct chemotherapy responses is essential. ...Hence, a combination of …
Nowadays, chemotherapy and immunotherapy remain the major treatment strategies for Triple-Negative Breast Cancer (TNBC). Ident …
Redox/NIR dual-responsive glutathione extended polyurethane urea electrospun membranes for synergistic chemo-photothermal therapy.
Martorana A, Puleo G, Miceli GC, Cancilla F, Licciardi M, Pitarresi G, Tranchina L, Marrale M, Palumbo FS. Martorana A, et al. Int J Pharm. 2025 Jan 25;669:125108. doi: 10.1016/j.ijpharm.2024.125108. Epub 2024 Dec 19. Int J Pharm. 2025. PMID: 39708849 Free article.
Despite advancements in cancer treatments, therapies frequently exhibit high cytotoxicity, and surgery remains the predominant method for treating most solid tumors, often with limited success in preventing post-surgical recurrence. ...Moreover, their excellent phototherma …
Despite advancements in cancer treatments, therapies frequently exhibit high cytotoxicity, and surgery remains the predominant method …
Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan.
Tokat ÜM, Adibi A, Aydın E, Bilgiç ŞN, Özgü E, Tutar O, Demiray M. Tokat ÜM, et al. Front Oncol. 2025 Jan 21;14:1484750. doi: 10.3389/fonc.2024.1484750. eCollection 2024. Front Oncol. 2025. PMID: 39931207 Free PMC article.
Breast cancer (BC) is the leading cause of cancer-related mortality among women. The backbone of first-line treatment in HR+/HER2+ BC is dual anti-HER2 blockade combined with taxane chemotherapy. ...
Breast cancer (BC) is the leading cause of cancer-related mortality among women. The backbone of first-line treatment i …
A synchronous occurrence of breast cancer and pleural mesothelioma: a case report.
Ahmad Z, Jehanzeb H, Hussain SN, Umar M, Saleem H. Ahmad Z, et al. J Med Case Rep. 2025 Jan 20;19(1):25. doi: 10.1186/s13256-024-04949-7. J Med Case Rep. 2025. PMID: 39833869 Free PMC article.
Breast cancer is the most common sporadic cancer among women, and a small percentage of cases are related to genetic factors, such as BRCA1/2 and BRCA1-associated protein-1 mutations. While breast cancer can be linked with other primary malignan …
Breast cancer is the most common sporadic cancer among women, and a small percentage of cases are related to genetic fa …
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.
Slomovitz BM, Cibula D, Lv W, Ortaç F, Hietanen S, Backes F, Kikuchi A, Lorusso D, Dańska-Bidzińska A, Samouëlian V, Barretina-Ginesta MP, Vulsteke C, Lai CH, Pothuri B, Zhang Y, Magallanes-Maciel M, Amit A, Guarneri V, Zagouri F, Bell M, Welz J, Eminowicz G, Hruda M, Willmott LJ, Lichfield J, Wang W, Orlowski R, Aktan G, Gladieff L, Van Gorp T. Slomovitz BM, et al. J Clin Oncol. 2025 Jan 20;43(3):251-259. doi: 10.1200/JCO-24-01887. Epub 2024 Oct 16. J Clin Oncol. 2025. PMID: 39411812 Free PMC article. Clinical Trial.
Mismatch repair-deficient (dMMR) endometrial cancer (EC) is an inflamed phenotype with poor outcomes when meeting high-risk criteria and limited treatment options in the adjuvant setting. ...
Mismatch repair-deficient (dMMR) endometrial cancer (EC) is an inflamed phenotype with poor outcomes when meeting high-risk criteria …
Coasting related to taxane-induced peripheral neuropathy in patients with breast cancer: a systematic review.
Kruse FL, Bille MB, Lendorf ME, Vaabengaard S, Birk S. Kruse FL, et al. Acta Oncol. 2025 Jan 15;64:78-86. doi: 10.2340/1651-226X.2025.42109. Acta Oncol. 2025. PMID: 39815403 Free PMC article.
The aim of this review is to examine the incidence and severity of coasting in CIPN in patients with breast cancer. Patient/material and methods: MEDLINE, Embase, clinicaltrials.gov, and medrivx.org were searched using terms related to taxanes, adverse effect …
The aim of this review is to examine the incidence and severity of coasting in CIPN in patients with breast cancer. Patient/ma …
Clinical evaluation and outcome in heart failure patients receiving chemotherapy with different anti-cancer agents.
Sunaga T, Okada T, Iso Y, Ebato M, Toshida T, Nawata S, Suzuki H, Kogo M. Sunaga T, et al. ESC Heart Fail. 2025 Jan 13. doi: 10.1002/ehf2.15204. Online ahead of print. ESC Heart Fail. 2025. PMID: 39801274 Free article.
The primary endpoint was readmission. RESULTS: Colon, lung, breast and prostate cancers accounted for >60% of all cancer types. After PS matching, readmission was significantly more frequently observed in patients with chemotherapy than those without [odds ratio …
The primary endpoint was readmission. RESULTS: Colon, lung, breast and prostate cancers accounted for >60% of all cancer ty …
Structure-Based Discovery of MolPort-137: A Novel Autotaxin Inhibitor That Improves Paclitaxel Efficacy.
Rai P, Clark CJ, Kardam V, Womack CB, Thammathong J, Norman DD, Tigyi GJ, Bicker K, Weissmiller AM, Dubey KD, Banerjee S. Rai P, et al. Int J Mol Sci. 2025 Jan 12;26(2):597. doi: 10.3390/ijms26020597. Int J Mol Sci. 2025. PMID: 39859312 Free PMC article.
The autotaxin-lysophosphatidic acid receptor (ATX-LPAR) signaling axis is pivotal in various clinical conditions, including cancer and autoimmune disorders. This axis promotes tumorigenicity by interacting with the tumor microenvironment, facilitating metastasis, and conce …
The autotaxin-lysophosphatidic acid receptor (ATX-LPAR) signaling axis is pivotal in various clinical conditions, including cancer an …
Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial-Mesenchymal Transition.
Błaszczak E, Miziak P, Odrzywolski A, Baran M, Gumbarewicz E, Stepulak A. Błaszczak E, et al. Cancers (Basel). 2025 Jan 12;17(2):228. doi: 10.3390/cancers17020228. Cancers (Basel). 2025. PMID: 39858010 Free PMC article. Review.
Triple-negative breast cancer (TNBC) is one of the most difficult subtypes of breast cancer to treat due to its distinct clinical and molecular characteristics. Patients with TNBC face a high recurrence rate, an increased risk of metastasis, and lower …
Triple-negative breast cancer (TNBC) is one of the most difficult subtypes of breast cancer to treat due to its …
RSL3 induces ferroptosis by activating the NF-kappaB signalling pathway to enhance the chemosensitivity of triple-negative breast cancer cells to paclitaxel.
Yuan J, Liu C, Jiang C, Liu N, Yang Z, Xing H. Yuan J, et al. Sci Rep. 2025 Jan 11;15(1):1654. doi: 10.1038/s41598-025-85774-w. Sci Rep. 2025. PMID: 39794456 Free PMC article.
Chemotherapy resistance in triple-negative breast cancer (TNBC) leads to poor therapeutic effects and a poor prognosis. Given that paclitaxel-based chemotherapy is the main treatment method for TNBC, enhancing its chemosensitivity has been a research focus. ...
Chemotherapy resistance in triple-negative breast cancer (TNBC) leads to poor therapeutic effects and a poor prognosis. Given …
The effect of hand and foot exercises on peripheral neuropathy and quality of life in women with breast cancer: a randomized controlled trial.
Uysal N, Ünal Toprak F. Uysal N, et al. Support Care Cancer. 2025 Jan 8;33(2):83. doi: 10.1007/s00520-025-09145-x. Support Care Cancer. 2025. PMID: 39779496 Free PMC article. Clinical Trial.
The aim of this study is to determine the effects of hand and foot exercises on chemotherapy-induced peripheral neuropathy and quality of life in women with breast cancer. METHODS: The sample of this randomized controlled trial study consisted of 79 women with br …
The aim of this study is to determine the effects of hand and foot exercises on chemotherapy-induced peripheral neuropathy and quality of li …
Severe Deficiency of Vitamin D and Anthracycline-Taxane Regimen are associated with Cachexia Following Breast Cancer Chemotherapy: A Single Center Assessment Using Two Consensus-Based Criteria.
Hutajulu SH, Aresy S, Astari YK, Wiranata JA, Puspitaningtyas H, Sulistyoningrum DC, Taroeno-Hariadi KW, Kurnianda J, Purwanto I, Hardianti MS. Hutajulu SH, et al. Asian Pac J Cancer Prev. 2025 Jan 1;26(1):189-197. doi: 10.31557/APJCP.2025.26.1.189. Asian Pac J Cancer Prev. 2025. PMID: 39874001 Free article.
BACKGROUND: Cancer cachexia in breast cancer (BC) patients is not commonly reported, particularly in Indonesia. ...Vitamin D severe deficiency was associated with an increased risk of cachexia (OR 2.47, 95%CI 1.19-5.11, p=0.014 for Fearon; and OR 2.47, 95%CI …
BACKGROUND: Cancer cachexia in breast cancer (BC) patients is not commonly reported, particularly in Indonesia. ...Vita …
circUBR5 promotes ribosome biogenesis and induces docetaxel resistance in triple-negative breast cancer cell lines via the miR-340-5p/CMTM6/c-MYC axis.
Wang X, Wang X, Gu J, Wei Y, Wang Y. Wang X, et al. Neoplasia. 2025 Jan;59:101062. doi: 10.1016/j.neo.2024.101062. Epub 2024 Dec 12. Neoplasia. 2025. PMID: 39672097 Free PMC article.
OBJECTIVE: Docetaxel (DTX) represents an effective chemotherapeutic agent for treating triple-negative breast cancer (TNBC), but the efficacy is strongly limited by drug resistance. c-MYC-mediated ribosome biogenesis is considered a feasible strategy to confront che …
OBJECTIVE: Docetaxel (DTX) represents an effective chemotherapeutic agent for treating triple-negative breast cancer (TNBC), b …
Utidelone combined with anti-angiogenic therapy for the treatment of anthracycline/taxane-treated and endocrine-resistant HR(+/)HER2(-) refractory breast cancer with brain metastases: A case report.
Bai X, Liu M, Chen X, Song L, Zhang J, Song Q, Xie X, Lan X, Chen L, Huang J, Du C. Bai X, et al. Oncol Lett. 2024 Oct 23;29(1):25. doi: 10.3892/ol.2024.14771. eCollection 2025 Jan. Oncol Lett. 2024. PMID: 39512500 Free PMC article.
For patients with hormone receptor-positive (HR(+)) and human epidermal growth factor receptor 2-negative (HER2(-)) metastatic breast cancer (mBC), the treatment choices become more complex after progression on first-line CDK4/6 inhibitors combined with endocrine th …
For patients with hormone receptor-positive (HR(+)) and human epidermal growth factor receptor 2-negative (HER2(-)) metastatic breast …
An exploration of the optimal combination chemotherapy regimen based on neoadjuvant therapy containing pyrotinib for HER2-positive breast cancer: A multicenter real-world study.
Wang S, Jin Z, Li Z, Zhu G, Liu B, Zhang D, Tang S, Yao F, Wen J, Zhao Y, Wang X, Jin F, Wang J. Wang S, et al. Transl Oncol. 2025 Jan;51:102173. doi: 10.1016/j.tranon.2024.102173. Epub 2024 Nov 5. Transl Oncol. 2025. PMID: 39504711 Free PMC article.
BACKGROUND: The combination of pyrotinib (Py) with cytotoxic agents proved to be effective in early human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). However, the optimal chemotherapy regimen is unknown. This study attempts to explore it f …
BACKGROUND: The combination of pyrotinib (Py) with cytotoxic agents proved to be effective in early human epidermal growth factor receptor 2 …
Beyond endocrine resistance: estrogen receptor (ESR1) activating mutations mediate chemotherapy resistance through the JNK/c-Jun MDR1 pathway in breast cancer.
Taya M, Merenbakh-Lamin K, Zubkov A, Honig Z, Kurolap A, Mayer O, Shomron N, Wolf I, Rubinek T. Taya M, et al. Breast Cancer Res Treat. 2025 Jan;209(2):431-449. doi: 10.1007/s10549-024-07507-3. Epub 2024 Oct 29. Breast Cancer Res Treat. 2025. PMID: 39470848 Free PMC article.
PURPOSE: All patients with metastatic breast cancer (MBC) expressing estrogen receptor-alpha (ESR1) will eventually develop resistance to endocrine therapies. ...
PURPOSE: All patients with metastatic breast cancer (MBC) expressing estrogen receptor-alpha (ESR1) will eventually develop re …
Therapy-Related Acute Promyelocytic Leukemia: Case Series and Current Insights.
Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Morelli R, Rossi T, Neri A, Morabito F, Gentile M, Vigna E. Bruzzese A, et al. Eur J Haematol. 2025 Jan;114(1):195-198. doi: 10.1111/ejh.14327. Epub 2024 Oct 13. Eur J Haematol. 2025. PMID: 39397152 Free PMC article.
The first case involved a 71-year-old man with colorectal and breast cancer, who developed low-risk t-APL and achieved complete remission (CR) with ATRA alone. A second 71-year-old man case with colorectal cancer developed high-risk t-APL with PML/RARA and FL …
The first case involved a 71-year-old man with colorectal and breast cancer, who developed low-risk t-APL and achieved complet …
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
Jacob S, Christofferson A, Fisch S, Norwood P, Castillo P, Yu H, Hirst G, Soliman H, Nanda R, Mukhtar RA, Ewing C, Majure M, Melisko M, Rugo HS, Esserman L, Price E, Chien AJ. Jacob S, et al. Breast Cancer Res Treat. 2025 Jan;209(1):147-159. doi: 10.1007/s10549-024-07481-w. Epub 2024 Sep 21. Breast Cancer Res Treat. 2025. PMID: 39305392 Free PMC article. Clinical Trial.
METHODS: Patients with stage 2-3 HER2-negative breast cancer were randomized to weekly paclitaxel (control), weekly paclitaxel and pembrolizumab, or weekly paclitaxel, pembrolizumab and intra-tumoral injection of SD-101, a TLR9 agonist. ...There was no association b …
METHODS: Patients with stage 2-3 HER2-negative breast cancer were randomized to weekly paclitaxel (control), weekly paclitaxel …
Genetic variants and social benefit receipt in premenopausal women with breast cancer treated with docetaxel: a Danish population-based cohort study.
Schmidt JA, Hjorth CF, Farkas DK, Damkier P, Feddersen S, Hamilton-Dutoit S, Ejlertsen B, Lash TL, Ahern TP, Cronin-Fenton D. Schmidt JA, et al. Breast Cancer Res Treat. 2025 Jan;209(1):73-84. doi: 10.1007/s10549-024-07474-9. Epub 2024 Sep 20. Breast Cancer Res Treat. 2025. PMID: 39302578 Free PMC article.
PURPOSE: Breast cancer patients' need for social benefits may increase following taxane-based chemotherapy, due to long-lasting side effects. ...METHODS: From the Danish Breast Cancer Group, we identified premenopausal women diagnosed with stage …
PURPOSE: Breast cancer patients' need for social benefits may increase following taxane-based chemotherapy, due to long …
Taxane Toxicity.
Ismail U, Killeen RB. Ismail U, et al. 2023 Mar 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Mar 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 36943973 Free Books & Documents.
FDA first approved docetaxel in 1996 for the treatment of metastatic breast cancer. Currently, it is approved for use in non-small cell lung cancer, head and neck cancer, gastric cancer, prostate cancer, and ovarian cancer. Cabazit …
FDA first approved docetaxel in 1996 for the treatment of metastatic breast cancer. Currently, it is approved for use in non-s …
Trastuzumab.
Greenblatt K, Khaddour K. Greenblatt K, et al. 2024 Jun 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Jun 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30335279 Free Books & Documents.
Trastuzumab is an FDA-approved antineoplastic biologic that targets HER2-positive breast and gastric cancer. This activity outlines trastuzumab's various indications and off-label uses, including its combination with anthracycline or taxane-based chemotherapy …
Trastuzumab is an FDA-approved antineoplastic biologic that targets HER2-positive breast and gastric cancer. This activity out …
NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression.
Reddy T, Puri A, Guzman-Rojas L, Thomas C, Qian W, Zhou J, Zhao H, Mahboubi B, Oo A, Cho YJ, Kim B, Thaiparambil J, Rosato R, Martinez KO, Chervo MF, Ayerbe C, Giese N, Wink D, Lockett S, Wong S, Chang J, Krishnamurthy S, Yam C, Moulder S, Piwnica-Worms H, Meric-Bernstam F, Chang J. Reddy T, et al. Nat Commun. 2024 Dec 30;15(1):10737. doi: 10.1038/s41467-024-54651-x. Nat Commun. 2024. PMID: 39737957 Free PMC article.
Metaplastic breast cancer (MpBC) is a highly chemoresistant subtype of breast cancer with no standardized therapy options. A clinical study in anthracycline-refractory MpBC patients suggested that nitric oxide synthase (NOS) inhibitor NG-monomethyl-l-a …
Metaplastic breast cancer (MpBC) is a highly chemoresistant subtype of breast cancer with no standardized therap …
First-line carboplatin-based chemotherapy may be beneficial for HER2-low advanced breast cancer: A retrospective analysis.
Li J, Tang Y, Chen Q, Lei S, Lu Y, Tan A, Xie W. Li J, et al. Medicine (Baltimore). 2024 Dec 27;103(52):e41082. doi: 10.1097/MD.0000000000041082. Medicine (Baltimore). 2024. PMID: 39969377 Free PMC article.
This retrospective study was designed to explore whether carboplatin based first-line treatment could improve outcomes in HER2-low advanced breast cancer, and to analyze potential factors affecting efficacy and prognosis. 103 patients with HER2-negative metastatic …
This retrospective study was designed to explore whether carboplatin based first-line treatment could improve outcomes in HER2-low advanced …
Tislelizumab plus AG regimen for long-term CR in 2 patients with metastatic BRCA-mutation pancreatic cancer: A case report.
Gao F, Xu X, Chen C, Lv L. Gao F, et al. Medicine (Baltimore). 2024 Dec 27;103(52):e40997. doi: 10.1097/MD.0000000000040997. Medicine (Baltimore). 2024. PMID: 39969335 Free PMC article.
RATIONALE: An increased risk of pancreatic cancer (PC) is associated with breast cancer susceptibility gene (BRCA) mutations. Given limited therapies, there remains an urgent need to explore novel treatment strategies. ...
RATIONALE: An increased risk of pancreatic cancer (PC) is associated with breast cancer susceptibility gene (BRCA) muta …
Depression risk among breast cancer survivors: a nationwide cohort study in South Korea.
Choi HL, Jeong SM, Jeon KH, Kim B, Jung W, Jeong A, Han K, Shin DW. Choi HL, et al. Breast Cancer Res. 2024 Dec 27;26(1):188. doi: 10.1186/s13058-024-01948-w. Breast Cancer Res. 2024. PMID: 39731197 Free PMC article.
BACKGROUND: Depression among breast cancer survivors is a significant concern affecting their long-term survivorship and quality of life. ...RESULTS: Breast cancer survivors with a mean (standard deviation) age of 51.5 (9.2) years had a 39% increased r …
BACKGROUND: Depression among breast cancer survivors is a significant concern affecting their long-term survivorship and quali …
A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline-Taxane Chemotherapy in Early HER-2 Negative Breast Cancer.
Giffoni de Mello Morais Mata D, Pezo RC, Chan KKW, Menjak I, Eisen A, Trudeau M. Giffoni de Mello Morais Mata D, et al. Curr Oncol. 2024 Dec 25;32(1):6. doi: 10.3390/curroncol32010006. Curr Oncol. 2024. PMID: 39851922 Free PMC article.
BACKGROUND: Anthracycline-taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). ...CONCLUSION: Our study shows that anthracycline-taxane regimens were the most commonly p …
BACKGROUND: Anthracycline-taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potenti …
Use of Gain-of-Function Screening to Identify miRNAs Involved in Paclitaxel Resistance in Triple-Negative Breast Cancer.
Nemours S, Solé C, Goicoechea I, Armesto M, Arestin M, Urruticoechea A, Rezola M, López IÁ, Schaapveld R, Schultz I, Zhang L, Lawrie CH. Nemours S, et al. Int J Mol Sci. 2024 Dec 20;25(24):13630. doi: 10.3390/ijms252413630. Int J Mol Sci. 2024. PMID: 39769392 Free PMC article.
Paclitaxel is a widely used chemotherapeutic agent for the treatment of breast cancer (BC), including as a front-line treatment for triple-negative breast cancer (TNBC) patients. ...We measured the levels of these miRNAs in breast cancer …
Paclitaxel is a widely used chemotherapeutic agent for the treatment of breast cancer (BC), including as a front-line treatmen …
Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival.
Schmidt M, Vernooij R, van Nuland M, Smeijsters E, Devriese L, Mohammad NH, Hermens T, Stammers J, Swart C, Egberts T, Haitjema S, Lammers L. Schmidt M, et al. BMC Cancer. 2024 Dec 18;24(1):1553. doi: 10.1186/s12885-024-13330-2. BMC Cancer. 2024. PMID: 39696046 Free PMC article.
METHODS: For this single-center retrospective observational study, patients treated with paclitaxel for breast, esophageal and ovarian cancer at the University Medical Centre Utrecht between 2011 and 2022 were identified from the Utrecht Patient Oriented Database (U …
METHODS: For this single-center retrospective observational study, patients treated with paclitaxel for breast, esophageal and ovaria …
Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.
Serrano García L, Jávega B, Llombart Cussac A, Gión M, Pérez-García JM, Cortés J, Fernández-Murga ML. Serrano García L, et al. Front Immunol. 2024 Dec 13;15:1513421. doi: 10.3389/fimmu.2024.1513421. eCollection 2024. Front Immunol. 2024. PMID: 39735530 Free PMC article. Review.
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of progesterone and estrogen receptors and low (or absent) HER2 expression. TNBC accounts for 15-20% of all breast cancers. It is associa …
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of p …
Pelophen B is a non-taxoid binding microtubule-stabilizing agent with promising preclinical anticancer properties.
Vermeulen S, Ernst S, Blondeel E, Xia Z, Rappu P, Heino J, Dedeyne S, Denys H, Sys G, Gijsels S, Depypere H, Tummers P, Ceelen W, Craciun L, Demetter P, Raes O, Hendrix A, Van der Eycken J, De Wever O. Vermeulen S, et al. Sci Rep. 2024 Dec 4;14(1):30188. doi: 10.1038/s41598-024-80672-z. Sci Rep. 2024. PMID: 39633082 Free PMC article.
Taxanes, such as paclitaxel (PTX), stabilize microtubules and are used as a first-line therapy in multiple cancer types. ...In conclusion, PPH results in remarkable anti-cancer activity in a range of preclinical models supporting further clinical investigatio …
Taxanes, such as paclitaxel (PTX), stabilize microtubules and are used as a first-line therapy in multiple cancer types. ...In …
Genetic Polymorphisms of DNA Repair Genes and their Influence on Paclitaxel based Chemotherapy Induced Toxicity Reactions in Breast Cancer Patients.
Datkhile KD, Reur PN, Kale SR, Gudur RA, Bhosale SJ, Gudur AK. Datkhile KD, et al. Asian Pac J Cancer Prev. 2024 Dec 1;25(12):4281-4292. doi: 10.31557/APJCP.2024.25.12.4281. Asian Pac J Cancer Prev. 2024. PMID: 39733420 Free article.
BACKGROUND: Systemic chemotherapy constitutes an indispensable component of breast cancer (BC) management, where therapeutic drug combinations such as anthracyclines, platinum compounds, and taxanes form the cornerstone of standard treatment protocols. Althou …
BACKGROUND: Systemic chemotherapy constitutes an indispensable component of breast cancer (BC) management, where therapeutic d …
Assessment of Hematological Toxicity of Adjuvant Chemotherapy in the Complex Therapy of Breast Cancer.
Sirota VB, Zhumakayeva SS, Kabildina NA, Dorogan DD, Bilyalova Z, Adekenov SM. Sirota VB, et al. Asian Pac J Cancer Prev. 2024 Dec 1;25(12):4123-4128. doi: 10.31557/APJCP.2024.25.12.4123. Asian Pac J Cancer Prev. 2024. PMID: 39733400 Free article.
Within the framework of multicenter clinical studies of the original anticancer drug "Arglabin" in the complex therapy of breast cancer (BC) in an increased dose on the basis of the Regional Oncological Dispensary, Karaganda, 80 patients BC were examined and treated …
Within the framework of multicenter clinical studies of the original anticancer drug "Arglabin" in the complex therapy of breast c …
Novel strategy for comprehensive therapy with sustainably complete response in a patient with limited-stage small cell lung cancer: a case report.
Jiang J, Gao J, Ben J, Wang G, Duan W, Liu H, Jin Q, Wang R, Lv J. Jiang J, et al. J Int Med Res. 2024 Dec;52(12):3000605241305429. doi: 10.1177/03000605241305429. J Int Med Res. 2024. PMID: 39719072 Free PMC article.
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with the poorest prognosis among all types of lung cancer. ...
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with the poorest prognosis among all types of lung cancer. …
Response to Carboplatin and Paclitaxel in the treatment of hereditary breast ovarian cancer syndrome (HBOC): a case report.
Mehmood F, Touseef M, Ashraf A, Rai IA. Mehmood F, et al. J Pak Med Assoc. 2024 Dec;74(12):2184-2187. doi: 10.47391/JPMA.20059. J Pak Med Assoc. 2024. PMID: 39658994 Free article.
The co-occurrence of primary breast cancer and primary ovarian cancer is an exceptional hereditary phenomenon and results from inherent mutations in critical genes like BRCA1/2, PALB2, TP53, CHEK1, and ATM. ...This dynamic treatment not only led to nearly com …
The co-occurrence of primary breast cancer and primary ovarian cancer is an exceptional hereditary phenomenon and resul …
Investigation of the Effects of Blocking Potassium Channels With 4-Aminopyridine on Paclitaxel Activity in Breast Cancer Cell Lines.
Cüce-Aydoğmuş EM, İnhan-Garip GA. Cüce-Aydoğmuş EM, et al. Cancer Rep (Hoboken). 2024 Dec;7(12):e70072. doi: 10.1002/cnr2.70072. Cancer Rep (Hoboken). 2024. PMID: 39648339 Free PMC article.
BACKGROUND: Paclitaxel (PTX) has been used as a chemotherapeutic agent for several malignancies, including breast cancer, and efforts to increase the efficiency of PTX are continuous. Previous studies have shown that the voltage-gated K(+) channels are over-expresse …
BACKGROUND: Paclitaxel (PTX) has been used as a chemotherapeutic agent for several malignancies, including breast cancer, and …
Targeted and cytotoxic inhibitors used in the treatment of breast cancer.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2024 Dec;210:107534. doi: 10.1016/j.phrs.2024.107534. Epub 2024 Dec 2. Pharmacol Res. 2024. PMID: 39631485 Free article. Review.
Breast cancer is the most commonly diagnosed malignancy and the fifth leading cause of cancer deaths worldwide. Surgery and radiation therapy are localized therapies for early-stage and metastatic breast cancer. The management of breast …
Breast cancer is the most commonly diagnosed malignancy and the fifth leading cause of cancer deaths worldwide. Surgery …
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study.
Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, Russo S, Riccardi F, Sini V, Cognetti F, Arpino G, Fabi A, Pugliese P, Collovà E, Fontana A, Puglisi F, Bighin C, Lambertini M, Del Mastro L. Molinelli C, et al. Eur J Cancer. 2024 Dec;213:115113. doi: 10.1016/j.ejca.2024.115113. Epub 2024 Nov 4. Eur J Cancer. 2024. PMID: 39536433 Free article.
METHODS: The GIM14/BIOMETA study (NCT02284581) is a retrospective/prospective study of the Gruppo Italiano Mammella evaluating treatment patterns and survival outcomes in patients with metastatic breast cancer (MBC). We retrieved data on patients with hormone recept …
METHODS: The GIM14/BIOMETA study (NCT02284581) is a retrospective/prospective study of the Gruppo Italiano Mammella evaluating treatment pat …
Reciprocal inhibition of NOTCH and SOX2 shapes tumor cell plasticity and therapeutic escape in triple-negative breast cancer.
Fournier M, Javary J, Roh V, Fournier N, Radtke F. Fournier M, et al. EMBO Mol Med. 2024 Dec;16(12):3184-3217. doi: 10.1038/s44321-024-00161-8. Epub 2024 Oct 30. EMBO Mol Med. 2024. PMID: 39478150 Free PMC article.
Cancer cell plasticity contributes significantly to the failure of chemo- and targeted therapies in triple-negative breast cancer (TNBC). ...This mechanism shapes divergent cell states with NOTCH positive TNBC being more epithelial-like, while SOX2 expression …
Cancer cell plasticity contributes significantly to the failure of chemo- and targeted therapies in triple-negative breast …
Neoadjuvant chemotherapy for radiation associated angiosarcoma (RAAS) of the breast: A retrospective single center study.
van der Burg SJC, Reijers SJM, Kuijpers A, Heimans L, Scholten AN, Haas RLM, Boven HV, Kolff WM, Vrancken Peeters MTFD, Kerst M, Seinstra BA, Steeghs N, van der Graaf WTA, Schrage YM, van Houdt WJ. van der Burg SJC, et al. Breast. 2024 Dec;78:103825. doi: 10.1016/j.breast.2024.103825. Epub 2024 Oct 21. Breast. 2024. PMID: 39476458 Free PMC article.
The aim of this study was to evaluate the potential benefit of taxane based NACT. METHODS: In this retrospective single center study, all patients with RAAS of the breast treated between 1994 and 2024 are included. ...CONCLUSION: In this study, neoadjuvant taxane …
The aim of this study was to evaluate the potential benefit of taxane based NACT. METHODS: In this retrospective single center study, …
Incidence, characteristics, and clinical impact of serious adverse events in patients with breast cancer receiving antineoplastic treatment in the ambulatory setting.
AbuAloush Z, Awad W, Mashni O, Shkakhwa F, Al-Faris A, Al-Omari M, Nabulsi S, Nazer L. AbuAloush Z, et al. Pharmacol Res Perspect. 2024 Dec;12(6):e70020. doi: 10.1002/prp2.70020. Pharmacol Res Perspect. 2024. PMID: 39468408 Free PMC article.
Patients with breast cancer experience various types of adverse events (AEs) during their treatment journey. We aimed to evaluate the incidence, characteristics, and impact of serious AEs in breast cancer patients receiving antineoplastic treatment in …
Patients with breast cancer experience various types of adverse events (AEs) during their treatment journey. We aimed to evalu …
Nodal involvement in patients with small, clinically node-negative HER2-positive breast cancer after staging with FDG-PET/CT and neoadjuvant systemic therapy.
van Olmen JP, Geurts VC, Vrancken Peeters MT, Drukker CA, Stokkel MP, Kok M, van Duijnhoven FH. van Olmen JP, et al. Breast. 2024 Dec;78:103822. doi: 10.1016/j.breast.2024.103822. Epub 2024 Oct 18. Breast. 2024. PMID: 39447417 Free PMC article.
BACKGROUND: Guidelines recommend systemic therapy for stage I HER2+ breast cancer (BC). Neoadjuvant systemic treatment (NAST) allows response-guided adjuvant treatment. ...
BACKGROUND: Guidelines recommend systemic therapy for stage I HER2+ breast cancer (BC). Neoadjuvant systemic treatment (NAST) …
An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors.
Eroglu Z, Synold T, Badie B, Liu A, Chowdhury A, Kilpatrick J, Blanchard S, Portnow J. Eroglu Z, et al. Cancer Chemother Pharmacol. 2024 Dec;94(6):807-813. doi: 10.1007/s00280-024-04711-2. Epub 2024 Oct 18. Cancer Chemother Pharmacol. 2024. PMID: 39422741 Free PMC article. Clinical Trial.
It is not as highly protein bound as the taxanes and is less vulnerable to extrusion by P-glycoprotein in the blood-brain barrier (BBB). ...Indeed, the small amount of published clinical data indicates eribulin may have some efficacy against breast cancer bra …
It is not as highly protein bound as the taxanes and is less vulnerable to extrusion by P-glycoprotein in the blood-brain barrier (BB …
Inflammation-based prognostic markers in patients with advanced or recurrent gastric cancer treated with nivolumab: Tokushukai REAl-world Data project 02 (TREAD 02).
Shimoyama R, Imamura Y, Uryu K, Mase T, Ohtaki M, Ohtani K, Shiragami M, Fujimura Y, Hayashi M, Shinozaki N, Minami H. Shimoyama R, et al. Mol Clin Oncol. 2024 Oct 3;21(6):90. doi: 10.3892/mco.2024.2788. eCollection 2024 Dec. Mol Clin Oncol. 2024. PMID: 39421231 Free PMC article.
In addition to blood test data, inflammation-based prognostic markers have been used to predict the prognosis of various types of cancer. However, several of these previous studies may be outdated, as they were conducted prior to the widespread adoption of immune checkpoin …
In addition to blood test data, inflammation-based prognostic markers have been used to predict the prognosis of various types of cancer …
Chemotherapy in older patients with early breast cancer.
Schmidt M, Loibl S. Schmidt M, et al. Breast. 2024 Dec;78:103821. doi: 10.1016/j.breast.2024.103821. Epub 2024 Oct 11. Breast. 2024. PMID: 39405593 Free PMC article. Review.
The incidence of breast cancer increases with age. Particularly in ageing societies, breast cancer has a significant impact on both the older patient and the healthcare system. ...The aim of our narrative review is to provide a concise overview of the …
The incidence of breast cancer increases with age. Particularly in ageing societies, breast cancer has a signifi …
Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors.
Nishimura T, Velaga R, Masuda N, Kawaguchi K, Kawaguchi S, Takada M, Maeshima Y, Tanaka S, Kikawa Y, Kadoya T, Bando H, Nakamura R, Yamamoto Y, Ueno T, Yasojima H, Ishiguro H, Morita S, Ohno S, Haga H, Matsuda F, Ogawa S, Toi M. Nishimura T, et al. Cancer Sci. 2024 Dec;115(12):3928-3942. doi: 10.1111/cas.16339. Epub 2024 Oct 7. Cancer Sci. 2024. PMID: 39375938 Free PMC article.
Our understanding of neoadjuvant treatment with microtubule inhibitors (MTIs) for triple negative breast cancer (TNBC) remains limited. To advance our understanding of the role of breast cancer driver genes' mutational status with pathological complete …
Our understanding of neoadjuvant treatment with microtubule inhibitors (MTIs) for triple negative breast cancer (TNBC) remains …
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Shatsky RA, et al. Nat Med. 2024 Dec;30(12):3737-3747. doi: 10.1038/s41591-024-03267-1. Epub 2024 Sep 14. Nat Med. 2024. PMID: 39277672 Free article. Clinical Trial.
Here we describe the results of incorporating a promising antibody-drug conjugate, datopotamab-deruxtecan (Dato-DXd) in combination with programmed cell death-ligand 1 inhibitor, durvalumab, as the first sequence of therapy in the I-SPY2.2 phase 2 neoadjuvant sequential multiple …
Here we describe the results of incorporating a promising antibody-drug conjugate, datopotamab-deruxtecan (Dato-DXd) in combination with pro …
Analysis of Factors Associated With Pathological Complete Response in Patients With HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy.
Stjepanovic N, Kumar S, Jerzak KJ, Trudeau M, Warner E, Cao X, Eisen A, Tran W, Pezo RC. Stjepanovic N, et al. Clin Breast Cancer. 2024 Dec;24(8):e723-e730. doi: 10.1016/j.clbc.2024.08.010. Epub 2024 Aug 22. Clin Breast Cancer. 2024. PMID: 39244392 Free article.
PURPOSE: This study aimed to examine the impact of the level of HER2 overexpression on pathologic and clinical outcomes in HER2-positive breast cancer (BC) patients treated with neoadjuvant therapy (NAT). METHODS: Women with Stage II or III HER2-positive BC who rece …
PURPOSE: This study aimed to examine the impact of the level of HER2 overexpression on pathologic and clinical outcomes in HER2-positive …
Can we counterbalance restricted access to innovation through specialized breast cancer care? The REAL-NOTE study.
Matos LV, Debiasi M, Padrão TG, Sousa B, Cardoso F. Matos LV, et al. Breast. 2024 Dec;78:103793. doi: 10.1016/j.breast.2024.103793. Epub 2024 Sep 3. Breast. 2024. PMID: 39232267 Free PMC article.
INTRODUCTION: The KEYNOTE-522 (KN-522) trial showed that the addition of pembrolizumab to standard chemotherapy improved pathological complete response (pCR) and event-free survival (EFS) for patients with early triple negative breast cancer (TNBC). We analyzed resu …
INTRODUCTION: The KEYNOTE-522 (KN-522) trial showed that the addition of pembrolizumab to standard chemotherapy improved pathological comple …
Enhancing docetaxel efficacy and reducing toxicity using biodegradable periodic mesoporous organosilica nanoparticles.
Nguyen Van H, Nguyen LHT, Mai NXD, Ha Nhat A, Le Thi Thu T, Nguyen Thi Bao A, Nguyen Thanh H, Le MT, Doan TLH. Nguyen Van H, et al. Heliyon. 2024 Nov 5;10(22):e40131. doi: 10.1016/j.heliyon.2024.e40131. eCollection 2024 Nov 30. Heliyon. 2024. PMID: 39584101 Free PMC article.
Taxanes, such as docetaxel (DTX), are pivotal in cancer therapy, showcasing remarkable efficacy against various cancers, like breast, lung, and ovarian malignancies. ...These findings highlight BPMO nanoparticles' potential in improving DTX delivery, solubili …
Taxanes, such as docetaxel (DTX), are pivotal in cancer therapy, showcasing remarkable efficacy against various cancers, like …
Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy.
Wang X, He Y, Li J, Wang T, Fan Z, Ouyang T. Wang X, et al. BMC Womens Health. 2024 Nov 27;24(1):629. doi: 10.1186/s12905-024-03441-0. BMC Womens Health. 2024. PMID: 39604957 Free PMC article. Clinical Trial.
BACKGROUND: Neoadjuvant chemotherapy (NAC) with anthracycline sequential paclitaxel is the standard regimen for triple negative breast cancer (TNBC), while TNBC with residual positive axillary lymph node after standard NAC indicates poor prognosis. ...
BACKGROUND: Neoadjuvant chemotherapy (NAC) with anthracycline sequential paclitaxel is the standard regimen for triple negative breast …
Glycemic load impacts the response of acquired resistance in breast cancer cells to chemotherapeutic drugs in vitro.
Adham SA, Al Kalbani A, Al Zeheimi N, Al Dalali M, Al Kharusi N, Siddiqi A, Al Maskari A. Adham SA, et al. PLoS One. 2024 Nov 22;19(11):e0311345. doi: 10.1371/journal.pone.0311345. eCollection 2024. PLoS One. 2024. PMID: 39576770 Free PMC article.
Resisting chemotherapy is a significant hurdle in treating breast cancer. Locally advanced breast cancer patients undergo four cycles of Adriamycin and Cyclophosphamide, followed by four cycles of Paclitaxel before surgery. ...We explored how breast …
Resisting chemotherapy is a significant hurdle in treating breast cancer. Locally advanced breast cancer patient …
Optimizing Neoadjuvant Treatment Response Prediction for Triple-Negative Breast Cancer Using Clinical Trial Data and Deep Auxiliary Learning.
Moon CI, Zhang B. Moon CI, et al. bioRxiv [Preprint]. 2024 Nov 19:2024.11.18.620337. doi: 10.1101/2024.11.18.620337. bioRxiv. 2024. PMID: 39605453 Free PMC article. Preprint.
MOTIVATION: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited treatment options and poor prognosis. ...The last scenario also provides an opportunity for validating prediction models on an independent dataset, …
MOTIVATION: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited treatmen …
Down-regulation of ESRP2 inhibits breast cancer cell proliferation via inhibiting cyclinD1.
He C, Chen Y, Zhang X, Feng H, Rao Y, Ji T, Wang W. He C, et al. Sci Rep. 2024 Nov 18;14(1):28475. doi: 10.1038/s41598-024-77980-9. Sci Rep. 2024. PMID: 39557898 Free PMC article.
However, the function and mechanism of ESRP2 in breast cancer (BC) remain unclear. The distribution of ESRP2 expression in breast cancer and the correlation between ESRP2 expression and the overall survival rate were detected by The Cancer Genom …
However, the function and mechanism of ESRP2 in breast cancer (BC) remain unclear. The distribution of ESRP2 expression in …
Stable Porous Organic Cage Nanocapsules for pH-Responsive Anticancer Drug Delivery for Precise Tumor Therapy.
Deng Y, Du Z, Du S, Li N, Wang W, Su K, Yuan D. Deng Y, et al. ACS Appl Bio Mater. 2024 Nov 18;7(11):7535-7543. doi: 10.1021/acsabm.4c01123. Epub 2024 Oct 12. ACS Appl Bio Mater. 2024. PMID: 39395005 Free PMC article.
Herein, a porous organic cage (POC) is applied to paclitaxel (PTX) drug delivery for cancer therapy for the first time. Specifically, water-soluble, stable, and biocompatible POC-based nanocapsules (PTX@POC@RH40) with PTX encapsulation efficiency over 98% can be synthesize …
Herein, a porous organic cage (POC) is applied to paclitaxel (PTX) drug delivery for cancer therapy for the first time. Specifically, …
FATS inhibits the Wnt pathway and induces apoptosis through degradation of MYH9 and enhances sensitivity to paclitaxel in breast cancer.
Song JX, Wang Y, Hua ZP, Huang Y, Hu LF, Tian MR, Qiu L, Liu H, Zhang J. Song JX, et al. Cell Death Dis. 2024 Nov 16;15(11):835. doi: 10.1038/s41419-024-07164-w. Cell Death Dis. 2024. PMID: 39550407 Free PMC article.
By overexpressing FATS and MYH9, we demonstrated that FATS enhanced paclitaxel-induced apoptosis in breast cancer cells by degrading MYH9 to downregulate the Wnt pathway. We also demonstrated in a mouse xenograft model that FATS significantly increased the chemosens …
By overexpressing FATS and MYH9, we demonstrated that FATS enhanced paclitaxel-induced apoptosis in breast cancer cells by deg …
Rg3-lipo biomimetic delivery of paclitaxel enhances targeting of tumors and myeloid-derived suppressor cells.
Shen Y, Zhong B, Zheng W, Wang D, Chen L, Song H, Pan X, Mo S, Jin B, Cui H, Zhan H, Luo F, Liu J. Shen Y, et al. J Clin Invest. 2024 Nov 15;134(22):e178617. doi: 10.1172/JCI178617. J Clin Invest. 2024. PMID: 39545407 Free PMC article.
With its glycosyl moieties recognizing tumor cells via the glucose transporter Glut1, PTX-Rg3-lipo inhibited gastric, breast, and esophageal cancers in human cancer cell lines, tumor-bearing mice, and patient-derived xenograft models. ...Taken together, we supply su …
With its glycosyl moieties recognizing tumor cells via the glucose transporter Glut1, PTX-Rg3-lipo inhibited gastric, breast, and eso …
Unveiling the Hidden Risks: An Update Decade-Long Analysis of Abraxane-Related Adverse Events from the FAERS Database.
Zhao YC, Li X, Wang CQ, Jiao Y, Shen YN, Wang TJ, Zhang CH. Zhao YC, et al. Int J Nanomedicine. 2024 Nov 14;19:11847-11858. doi: 10.2147/IJN.S490400. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39558918 Free PMC article.
PURPOSE: Abraxane (nanoparticle albumin-bound paclitaxel) is a chemotherapeutic employed commonly for the management of various cancers including breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma. Although it has clinically beneficial p …
PURPOSE: Abraxane (nanoparticle albumin-bound paclitaxel) is a chemotherapeutic employed commonly for the management of various cancers incl …
DLL4-targeted CAR-T therapy sensitizes neoadjuvant chemotherapy via eliminating cancer stem cells and reshaping immune microenvironment in HER2(+) breast cancer.
Yan J, Xie Y, Liu Z, Yang Y, Zhou T. Yan J, et al. J Immunother Cancer. 2024 Nov 14;12(11):e009636. doi: 10.1136/jitc-2024-009636. J Immunother Cancer. 2024. PMID: 39542653 Free PMC article.
BACKGROUND: Neoadjuvant therapy with trastuzumab, pertuzumab and paclitaxel (THP) has significantly improved the prognosis of patients with human epidermal growth factor receptor 2 (HER2)(+) breast cancer (BC). However, there remains a subset of non-responsive patie …
BACKGROUND: Neoadjuvant therapy with trastuzumab, pertuzumab and paclitaxel (THP) has significantly improved the prognosis of patients with …
Deciphering the Role of ASPM in Breast Cancer: A Comprehensive Multicohort Study.
Ibrahim A, Atallah NM, Makhlouf S, Toss MS, Green A, Rakha E. Ibrahim A, et al. Cancers (Basel). 2024 Nov 13;16(22):3814. doi: 10.3390/cancers16223814. Cancers (Basel). 2024. PMID: 39594769 Free PMC article.
BACKGROUND: Assembly factor for spindle microtubules (ASPM) has gained significant attention in cancer research due to its association with tumor growth and progression. Through the analysis of large-scale genomic datasets, ASPM has been identified as the top upregulated g …
BACKGROUND: Assembly factor for spindle microtubules (ASPM) has gained significant attention in cancer research due to its associatio …
The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer.
Manouchehri JM, Datta J, Marcho LM, Reardon JJ, Stover D, Wesolowski R, Borate U, Cheng TD, Schnell PM, Ramaswamy B, Sizemore GM, Rubinstein MP, Cherian MA. Manouchehri JM, et al. Breast Cancer Res. 2024 Nov 6;26(1):153. doi: 10.1186/s13058-024-01906-6. Breast Cancer Res. 2024. PMID: 39506780 Free PMC article.
BACKGROUND: Breast cancer, one of the most common forms of cancer, is associated with the highest cancer-related mortality among women worldwide. In comparison to other types of breast cancer, patients diagnosed with the triple-negative …
BACKGROUND: Breast cancer, one of the most common forms of cancer, is associated with the highest cancer-related …
Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy.
Lee YJ, Noh WC, Gwark S, Kim HA, Ryu JM, Kim SI, Lee EG, Im SA, Jung Y, Park MH, Park KH, Kang SH, Jeong J, Park E, Kim SY, Lee MH, Kim LS, Lim W, Kim S, Kim HJ. Lee YJ, et al. Breast Cancer Res. 2024 Nov 5;26(1):152. doi: 10.1186/s13058-024-01903-9. Breast Cancer Res. 2024. PMID: 39501399 Free PMC article. Clinical Trial.

In multivariable analysis, younger age (< 35 vs. 45, HR 7.85, 95% CI 4.63-13.30, p < 0.0001), anthracycline-based chemotherapy without taxane (vs. with taxane, HR 1.81, 95% CI 1.37-2.38, p < 0.0001), and chemotherapy duration ( 90 days vs. > 90 days, HR

…

In multivariable analysis, younger age (< 35 vs. 45, HR 7.85, 95% CI 4.63-13.30, p < 0.0001), anthracycline-based chemotherapy without

…
In Vitro Antitumor and Antimetastatic Activity of a New Lapachol Derivative against Metastatic Breast Carcinoma.
Rissate FMM, De Souza LR, Otoni FM, Kim B, Dos Santos HB, Thomé RG, Alves RJ, Ribeiro RIMA. Rissate FMM, et al. Asian Pac J Cancer Prev. 2024 Nov 1;25(11):3935-3946. doi: 10.31557/APJCP.2024.25.11.3935. Asian Pac J Cancer Prev. 2024. PMID: 39611918 Free article.
OBJECTIVE: Breast cancer represents the most prevalent type of tumor throughout the world. Considering the side effects caused by the available treatments, the resistance acquired by cells to cytotoxic agents, and metastasis, it is necessary to search for new source …
OBJECTIVE: Breast cancer represents the most prevalent type of tumor throughout the world. Considering the side effects caused …
Clinicopathological factors affecting response and survival in stage III breast cancer patients undergoing a dose-dense neoadjuvant regimen.
Truong TKO, Vu HT, Bui VQ, Nguyen HB. Truong TKO, et al. Clin Ter. 2024 Nov-Dec;175(6):412-421. doi: 10.7417/CT.2024.5148. Clin Ter. 2024. PMID: 39584761 Free article.
INTRODUCTION: Identifying predictors of pathological complete response (pCR) and long-term outcomes after neoadjuvant treatment for breast cancer is needed to individualize treatment and patient monitoring. This study aimed to investigate clinicopathological factors …
INTRODUCTION: Identifying predictors of pathological complete response (pCR) and long-term outcomes after neoadjuvant treatment for breas …
Modulating versatile pathways using a cleavable PEG shell and EGFR-targeted nanoparticles to deliver CRISPR-Cas9 and docetaxel for triple-negative breast cancer inhibition.
Lo YL, Hong CJ, Wang CS, Yang CP. Lo YL, et al. Arch Pharm Res. 2024 Nov;47(10-11):829-853. doi: 10.1007/s12272-024-01514-0. Epub 2024 Nov 1. Arch Pharm Res. 2024. PMID: 39482441 Free PMC article.
Human antigen R (HuR), an RNA-binding protein, is implicated in regulating mRNA stability and translation in cancer, especially in triple-negative breast cancer (TNBC), a highly aggressive form. CRISPR/Cas9-mediated HuR knockout (HuR CRISPR) presents a promis …
Human antigen R (HuR), an RNA-binding protein, is implicated in regulating mRNA stability and translation in cancer, especially in tr …
Targeting hypoxia in combination with paclitaxel to enhance therapeutic efficacy in breast and ovarian cancer.
Svajda L, Ranđelović I, Surguta SE, Baranyi M, Cserepes M, Tóvári J. Svajda L, et al. Biomed Pharmacother. 2024 Nov;180:117601. doi: 10.1016/j.biopha.2024.117601. Epub 2024 Oct 30. Biomed Pharmacother. 2024. PMID: 39476764 Free article.
The most significant findings were detected in triple-negative breast cancer cell lines, where we observed synergism. The drug combination effectively impeded tumor growth and metastasis formation in an in vivo orthotopic triple-negative breast cancer …
The most significant findings were detected in triple-negative breast cancer cell lines, where we observed synergism. The drug …
Gilteritinib reverses ABCB1-mediated multidrug resistance: Preclinical in vitro and animal investigations.
Zhang M, She ML, Chen J, Zeng XQ, Xiong QQ, Cen YH, Ye JA, Qiu GB, Yang SY, Ren GH. Zhang M, et al. Biomed Pharmacother. 2024 Nov;180:117603. doi: 10.1016/j.biopha.2024.117603. Epub 2024 Oct 30. Biomed Pharmacother. 2024. PMID: 39471652 Free article.
Multi-drug resistance (MDR) poses a significant challenge to cancer treatment. Targeting ATP-binding cassette subfamily B member 1 (ABCB1) is a viable strategy for overcoming MDR. ...At nontoxic levels, gilteritinib significantly increased the susceptibility of cancer …
Multi-drug resistance (MDR) poses a significant challenge to cancer treatment. Targeting ATP-binding cassette subfamily B member 1 (A …
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy.
Egeland EV, Seip K, Skourti E, Øy GF, Pettersen SJ, Pandya AD, Dahle MA, Haugen MH, Kristian A, Nakken S, Engebraaten O, Mælandsmo GM, Prasmickaite L. Egeland EV, et al. Br J Cancer. 2024 Nov;131(10):1656-1667. doi: 10.1038/s41416-024-02875-5. Epub 2024 Oct 10. Br J Cancer. 2024. PMID: 39390250 Free PMC article.
BACKGROUND: Resistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of triple negative breast cancer (TNBC). By dissecting molecular pathways associated with treatment resistance, …
BACKGROUND: Resistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinic …
Microfluidic formulation, cryoprotection and long-term stability of paclitaxel-loaded π electron-stabilized polymeric micelles.
Mihyar R, Shalmani AA, Wildt V, Sheybanifard M, Wang A, May JN, Shahzad S, Buhl EM, Rütten S, Behrens D, Walther W, Tiboni M, Casettari L, Buyel JF, Rijcken CJF, Hennink WE, von Stillfried S, Kiessling F, Shi Y, Metselaar JM, Lammers T, Peña Q. Mihyar R, et al. J Control Release. 2024 Nov;375:614-626. doi: 10.1016/j.jconrel.2024.08.041. Epub 2024 Sep 23. J Control Release. 2024. PMID: 39316925 Free article.
The pharmaceutical properties and preclinical performance (in terms of tolerability and tumor growth inhibition in a patient-derived triple-negative breast cancer xenograft mouse model) of paclitaxel-loaded micelles were successfully cryopreserved. ...
The pharmaceutical properties and preclinical performance (in terms of tolerability and tumor growth inhibition in a patient-derived triple- …
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
Dugo M, Huang CS, Egle D, Bermejo B, Zamagni C, Seitz RS, Nielsen TJ, Thill M, Antón-Torres A, Russo S, Ciruelos EM, Schweitzer BL, Ross DT, Galbardi B, Greil R, Semiglazov V, Gyorffy B, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Blasi O, Callari M, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Dugo M, et al. Clin Cancer Res. 2024 Nov 1;30(21):4900-4909. doi: 10.1158/1078-0432.CCR-24-0149. Clin Cancer Res. 2024. PMID: 39308141 Free PMC article. Clinical Trial.
PURPOSE: We assessed the 27-gene RT-qPCR-based DetermaIO assay and the same score calculated from RNA sequencing (RNA-seq) data as predictors of sensitivity to immune checkpoint therapy in the neoTRIPaPDL1 randomized trial that compared neoadjuvant carboplatin/nab-paclitaxel chem …
PURPOSE: We assessed the 27-gene RT-qPCR-based DetermaIO assay and the same score calculated from RNA sequencing (RNA-seq) data as predictor …
Efficacy and safety of nanoparticle albumin-bound paclitaxel compared with solvent-based paclitaxel in adjuvant therapy for breast cancer: A retrospective study.
Lv H, Hong Y, Zhang Y, Li S, Li B, Zhang M. Lv H, et al. Oncol Lett. 2024 Aug 23;28(5):509. doi: 10.3892/ol.2024.14642. eCollection 2024 Nov. Oncol Lett. 2024. PMID: 39268162 Free PMC article.
The current evidence for the use of nanoparticle albumin-bound paclitaxel (nab-PTX) for adjuvant breast cancer chemotherapy is insufficient. The present study aimed to assess the efficacy and toxicity of nab-PTX in comparison with solvent-based paclitaxel (sb-PTX) i …
The current evidence for the use of nanoparticle albumin-bound paclitaxel (nab-PTX) for adjuvant breast cancer chemotherapy is …
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.
Kitadai R, Shimoi T, Yazaki S, Okuma HS, Hoshino M, Ito M, Saito A, Kita S, Kojima Y, Nishikawa T, Sudo K, Noguchi E, Fujiwara Y, Yoshida M, Yonemori K. Kitadai R, et al. Breast Cancer. 2024 Nov;31(6):1037-1045. doi: 10.1007/s12282-024-01617-y. Epub 2024 Aug 14. Breast Cancer. 2024. PMID: 39141076 Free PMC article.
This study evaluated the clinicopathological features and outcomes of patients with advanced breast cancer showing HER2-low expression treated with eribulin or capecitabine, two treatment options after anthracycline and taxane treatment. ...CONCLUSIONS: Eribu …
This study evaluated the clinicopathological features and outcomes of patients with advanced breast cancer showing HER2-low ex …
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Garrett AM, Marcom PK, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Ruddy KJ, Waks AG, DeMeo M, Burstein HJ, Partridge AH, Dell'Orto P, Russo L, Krause E, Newhouse DJ, Kurt BB, Mittendorf EA, Schneider B, Prat A, Winer EP, Krop IE, Tolaney SM; Consortium of the TBCRC Translational Investigators; TBCRC Translational Investigators. Tarantino P, et al. J Clin Oncol. 2024 Nov;42(31):3652-3665. doi: 10.1200/JCO.23.02170. Epub 2024 Jun 27. J Clin Oncol. 2024. PMID: 38935923 Free PMC article. Clinical Trial.
METHODS: In the ATEMPT phase II trial, patients with stage I centrally confirmed HER2-positive breast cancer were randomly assigned 3:1 to adjuvant T-DM1 for 1 year or paclitaxel plus trastuzumab (TH). ...CONCLUSION: Adjuvant T-DM1 for 1 year leads to outstanding lo …
METHODS: In the ATEMPT phase II trial, patients with stage I centrally confirmed HER2-positive breast cancer were randomly ass …
Effectiveness and safety of neoadjuvant therapy in triple-negative breast cancer in a real-world population.
Galindo García C, Díaz Acedo R, Artacho Criado S, Rodríguez de la Borbolla Artacho M. Galindo García C, et al. Farm Hosp. 2024 Nov-Dec;48(6):278-285. doi: 10.1016/j.farma.2024.03.014. Epub 2024 May 9. Farm Hosp. 2024. PMID: 38724401 Free article. English, Spanish.
OBJECTIVE: Triple-negative breast cancer is a subtype of aggressive breast cancer. Our aim is to evaluate the effectiveness and safety of neoadjuvant treatment in early-stage triple-negative breast cancer and to identify predictors of pat …
OBJECTIVE: Triple-negative breast cancer is a subtype of aggressive breast cancer. Our aim is to evaluate the ef …
Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with Gastric Cancer Associated with Hereditary Breast and Ovarian Cancer.
Hayashi T, Sano K, Okada M, Muto M, Konishi I. Hayashi T, et al. Curr Oncol. 2024 Oct 29;31(11):6723-6734. doi: 10.3390/curroncol31110496. Curr Oncol. 2024. PMID: 39590127 Free PMC article.
Previous clinical studies have revealed that the bacterium secretes cytotoxin-associated gene A antigen, which inhibits the nuclear translocation of the breast cancer susceptibility gene 1 and 2 (BRCA1/2), a factor involved in DNA damage repair. ...Using the informa …
Previous clinical studies have revealed that the bacterium secretes cytotoxin-associated gene A antigen, which inhibits the nuclear transloc …
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.
He M, Jiang YZ, Gong Y, Fan L, Liu XY, Liu Y, Tang LC, Mo M, Hou YF, Di GH, Liu GY, Yu KD, Wu J, Yan X, Zeng XH, Fu DY, Song CG, Zhuang ZG, Wu KJ, Wang J, Wang ZH, Shao ZM. He M, et al. BMJ. 2024 Oct 23;387:e079603. doi: 10.1136/bmj-2024-079603. BMJ. 2024. PMID: 39442958 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the feasibility of using a multigene signature to tailor individualised adjuvant therapy for patients with operable triple negative breast cancer. DESIGN: Randomised, multicentre, open label, phase 3 trial. SETTING: 7 cancer centres in …
OBJECTIVE: To evaluate the feasibility of using a multigene signature to tailor individualised adjuvant therapy for patients with operable t …
Inhibition of NLRP3 inflammasome contributes to paclitaxel efficacy in triple negative breast cancer treatment.
Balahura Stămat LR, Dinescu S. Balahura Stămat LR, et al. Sci Rep. 2024 Oct 21;14(1):24753. doi: 10.1038/s41598-024-75805-3. Sci Rep. 2024. PMID: 39433537 Free PMC article.
Chronic inflammation and NLRP3 inflammasome activation are among the determining factors of breast malignancies. Paclitaxel (PTX) is a drug used in breast cancer treatment which sustains prolonged inflammation, reducing the effectiveness of chemotherapy. Cons …
Chronic inflammation and NLRP3 inflammasome activation are among the determining factors of breast malignancies. Paclitaxel (PTX) is …
Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides.
Bergstrom EN, Abbasi A, Díaz-Gay M, Galland L, Ladoire S, Lippman SM, Alexandrov LB. Bergstrom EN, et al. J Clin Oncol. 2024 Oct 20;42(30):3550-3560. doi: 10.1200/JCO.23.02641. Epub 2024 Jul 31. J Clin Oncol. 2024. PMID: 39083703 Free PMC article.
RESULTS: DeepHRD predicted HRD from held-out H&E-stained breast cancer slides in TCGA with an AUC of 0.81 (95% CI, 0.77 to 0.85). This performance was confirmed in two independent primary breast cancer cohorts (AUC, 0.76 [95% CI, 0.71 to 0.82]). .. …
RESULTS: DeepHRD predicted HRD from held-out H&E-stained breast cancer slides in TCGA with an AUC of 0.81 (95% CI, 0.77 to …
Breast Cancer Adjuvant Radiotherapy and Chemotherapy Sequencing: Sequential, Concomitant, or What Else? A Comprehensive Review of the Adjuvant Combinations Journey.
Lazzari G, Montagna A, D'Andrea B, Bianculli A, Calice G, Tucciariello R, Castaldo G, Metallo V, De Marco G, Benevento I. Lazzari G, et al. J Clin Med. 2024 Oct 19;13(20):6251. doi: 10.3390/jcm13206251. J Clin Med. 2024. PMID: 39458200 Free PMC article. Review.
Background: To date, in breast cancer (BC) treatment, adjuvant chemotherapy (A-CT) has preceded adjuvant radiotherapy (A-RT). ...This comprehensive review is a journey among the most important randomized, retrospective, and prospective studies that highlights the pa …
Background: To date, in breast cancer (BC) treatment, adjuvant chemotherapy (A-CT) has preceded adjuvant radiotherapy (A-RT). …
Enhanced docetaxel therapeutic effect using dual targeted SRL-2 and TA1 aptamer conjugated micelles in inhibition Balb/c mice breast cancer model.
Taghipour YD, Zarebkohan A, Salehi R, Talebi M, Rahbarghazi R, Khordadmehr M, Khavandkari S, Badparvar F, Torchilin VP. Taghipour YD, et al. Sci Rep. 2024 Oct 19;14(1):24603. doi: 10.1038/s41598-024-75042-8. Sci Rep. 2024. PMID: 39427007 Free PMC article.
Effective targeting and delivery of large amounts of medications into the cancer cells enhance their therapeutic efficacy through saturation of cellular defensive mechanisms, which is the most privilege of nano drug delivery systems (NDDS) compared to traditional approache …
Effective targeting and delivery of large amounts of medications into the cancer cells enhance their therapeutic efficacy through sat …
Human mesenchymal stroma/stem-like cell-derived taxol-loaded EVs/exosomes transfer anti-tumor microRNA signatures and express enhanced SDF-1-mediated tumor tropism.
Hass R, von der Ohe J, Luo T. Hass R, et al. Cell Commun Signal. 2024 Oct 17;22(1):506. doi: 10.1186/s12964-024-01886-2. Cell Commun Signal. 2024. PMID: 39420354 Free PMC article.
Cytotoxic effects of the different MSC-derived taxol-loaded EVs/exosomes were determined in five different GFP-transduced cancer cell lines and quantified by a fluoroscan assay with a GFP-detecting fluorimeter. ...CONCLUSIONS: These findings suggested a taxol-mediated incr …
Cytotoxic effects of the different MSC-derived taxol-loaded EVs/exosomes were determined in five different GFP-transduced cancer cell …
HER2-low non-metastatic breast cancer in Qatar-a nationwide retrospective cohort study to evaluate the response to neoadjuvant chemotherapy: a real-world analysis.
Kardousha A, Shehada W, Basha A, Nasser S, El Mistiri M, Hamad A, Bujassoum Al-Bader S, Elazzazy S. Kardousha A, et al. Front Oncol. 2024 Oct 16;14:1398100. doi: 10.3389/fonc.2024.1398100. eCollection 2024. Front Oncol. 2024. PMID: 39479022 Free PMC article.
Globally, breast cancer is the most prevalent cancer and one of the leading causes of cancer-related death among women. HER2-low breast cancer represents a recently identified molecular category within breast cancer characte …
Globally, breast cancer is the most prevalent cancer and one of the leading causes of cancer-related death among …
Pregnancy-associated triple-negative breast cancer: A case report and literature review.
Bao W, Ma X, Xue Y, Zou X, Guo Y. Bao W, et al. Medicine (Baltimore). 2024 Oct 11;103(41):e40059. doi: 10.1097/MD.0000000000040059. Medicine (Baltimore). 2024. PMID: 39465823 Free PMC article. Review.
This article reports a case of pregnancy-associated triple-negative breast cancer and describes the patient characteristics and systematic treatment of this type of breast cancer. ...During the examination of the left breast, a 6 by 8 cm sized m …
This article reports a case of pregnancy-associated triple-negative breast cancer and describes the patient characteristics an …
Tumor-associated macrophages/C-X-C motif chemokine ligand 1 promotes breast cancer autophagy-mediated chemoresistance via IGF1R/STAT3/HMGB1 signaling.
Yang B, Li G, Wang S, Zheng Y, Zhang J, Pan B, Wang N, Wang Z. Yang B, et al. Cell Death Dis. 2024 Oct 11;15(10):743. doi: 10.1038/s41419-024-07123-5. Cell Death Dis. 2024. PMID: 39394189 Free PMC article.
Autophagy-mediated chemoresistance is the core mechanism for therapeutic failure and poor prognosis in breast cancer. Breast cancer chemotherapy resistance is believed to be influenced by tumor-associated macrophages (TAMs), by which C-X-C motif chemok …
Autophagy-mediated chemoresistance is the core mechanism for therapeutic failure and poor prognosis in breast cancer. Breas …
Early taxane exposure and neurotoxicity in breast cancer patients.
Cimbro E, Dessì M, Ziranu P, Madeddu C, Atzori F, Lai E, Pretta A, Mariani S, Donisi C, Spanu D, Pozzari M, Murgia S, Saba G, Codipietro C, Palmas E, Sanna G, Semonella F, Sardo S, Finco G, Scartozzi M. Cimbro E, et al. Support Care Cancer. 2024 Oct 8;32(10):709. doi: 10.1007/s00520-024-08908-2. Support Care Cancer. 2024. PMID: 39375221 Free PMC article.
INTRODUCTION: Breast cancer is the most diagnosed tumor and a leading cause of cancer death in women worldwide. ...METHODS: Data from stage I-III breast cancer patients treated with taxane-based therapy between 2018 and 2022 were collecte …
INTRODUCTION: Breast cancer is the most diagnosed tumor and a leading cause of cancer death in women worldwide. ...METH …
Sjögren syndrome induced by anti PDL-1 treatment for TNBC: case report and review of literature.
Pellegrino C, D'Antonio C, Ierinò D, Onesti CE, Aschelter AM, Santini D, Mazzuca F. Pellegrino C, et al. Front Immunol. 2024 Oct 7;15:1417444. doi: 10.3389/fimmu.2024.1417444. eCollection 2024. Front Immunol. 2024. PMID: 39434886 Free PMC article. Review.
A CT scan in September 2022 showed lung nodules and lymph node involvement. A lung biopsy confirmed breast cancer metastasis. She started treatment with atezolizumab and nab-paclitaxel with evidence of a partial response. ...Further research is needed to optimize tr …
A CT scan in September 2022 showed lung nodules and lymph node involvement. A lung biopsy confirmed breast cancer metastasis. …
Dose delay, dose reduction, and early treatment discontinuation in Black and White women receiving chemotherapy for nonmetastatic breast cancer.
Forster M, Deal AM, Page A, Vohra S, Wardell AC, Pak J, Lund JL, Nyrop KA, Muss HB. Forster M, et al. Oncologist. 2024 Oct 3;29(10):e1246-e1259. doi: 10.1093/oncolo/oyae150. Oncologist. 2024. PMID: 38913986 Free PMC article.
BACKGROUND: To describe reasons for deviations from planned chemotherapy treatments in women with nonmetastatic breast cancer that contribute to less-than-planned receipt of chemotherapy. METHODS: Electronic medical records for patients receiving chemotherapy were r …
BACKGROUND: To describe reasons for deviations from planned chemotherapy treatments in women with nonmetastatic breast cancer …
Molecular Docking and Pharmacokinetic Profiling of Nab-paclitaxel as Advanced Chemotherapeutic Agent Against HER-2 Positive Breast Cancer Patients.
Mangilit NJD, Arkoncel ABS, Baylon KMD, Eslabra JMV, De Borja JLD, Nakama JG, Esmalla MSA, Labrador AM, Paulin JP, Santiago-Bautista MR. Mangilit NJD, et al. Asian Pac J Cancer Prev. 2024 Oct 1;25(10):3447-3456. doi: 10.31557/APJCP.2024.25.10.3447. Asian Pac J Cancer Prev. 2024. PMID: 39471010 Free PMC article.
OBJECTIVE: The main objective of the study is to explore the potential molecular benefits of Nab-paclitaxel as an effective advanced chemotherapeutic agent for HER2-positive breast cancer patients. Specifically, the study aims to assess Nab-paclitaxel as a potential …
OBJECTIVE: The main objective of the study is to explore the potential molecular benefits of Nab-paclitaxel as an effective advanced chemoth …
The First Report of Bickerstaff Brainstem Encephalitis Induced by Atezolizumab for Metastatic Breast Cancer.
Shimoyama K, Nakajima A, Minari Y. Shimoyama K, et al. Acta Med Okayama. 2024 Oct;78(5):407-412. doi: 10.18926/AMO/67665. Acta Med Okayama. 2024. PMID: 39467659 Free article.
Here we report the first case of Bickerstaff brainstem encephalitis (BBE) induced by an ICI. A woman in her 60s with metastatic breast cancer was treated with atezolizumab plus nab-paclitaxel once intravenously. Eighteen days later, she lost consciousness with ophth …
Here we report the first case of Bickerstaff brainstem encephalitis (BBE) induced by an ICI. A woman in her 60s with metastatic breast …
Prognostic and Predictive Markers for Early Stage Triple-Negative Breast Cancer Treated With Platinum-Based Neoadjuvant Chemotherapy.
Zhao Z, Li L, He M, Li Y, Ma X, Zhao B. Zhao Z, et al. Cancer Med. 2024 Oct;13(20):e70336. doi: 10.1002/cam4.70336. Cancer Med. 2024. PMID: 39445528 Free PMC article.
BACKGROUND: Emerging evidence has indicated possible efficacy benefit of platinum-based chemotherapy as neoadjuvant treatment for invasive ductal carcinoma triple-negative breast cancer (TNBC). However, it has not been endorsed by current guidelines due to highly co …
BACKGROUND: Emerging evidence has indicated possible efficacy benefit of platinum-based chemotherapy as neoadjuvant treatment for invasive d …
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study.
Yam C, Patel M, Hill HA, Sun R, Bassett RL Jr, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding QQ, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT. Yam C, et al. Cancer Res Commun. 2024 Oct 1;4(10):2823-2834. doi: 10.1158/2767-9764.CRC-24-0255. Cancer Res Commun. 2024. PMID: 39356138 Free PMC article. Clinical Trial.
PURPOSE: Epidermal growth factor receptor (EGFR) pathway activation causes chemotherapy resistance, and inhibition of the EGFR pathway sensitizes triple-negative breast cancer (TNBC) cells to chemotherapy in preclinical models. Given the high prevalence of EGFR over …
PURPOSE: Epidermal growth factor receptor (EGFR) pathway activation causes chemotherapy resistance, and inhibition of the EGFR pathway sensi …
A dramatic response to an immune checkpoint inhibitor plus chemotherapy in a patient with metastatic metaplastic carcinoma of the breast: A case report.
Koi Y, Tajiri W, Kawasaki J, Akiyoshi S, Ijichi H, Nakamura Y, Koga C, Koga Y, Taguchi K, Tokunaga E. Koi Y, et al. Thorac Cancer. 2024 Oct;15(28):2073-2076. doi: 10.1111/1759-7714.15433. Epub 2024 Sep 1. Thorac Cancer. 2024. PMID: 39219055 Free PMC article.
We present a unique case of metastatic metaplastic breast carcinoma responding dramatically to immunochemotherapy. A 46-year-old Japanese woman with primary metaplastic carcinoma of the breast, which was immunohistochemically confirmed to be triple-negative breas …
We present a unique case of metastatic metaplastic breast carcinoma responding dramatically to immunochemotherapy. A 46-year-old Japa …
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.
Dent RA, Kim SB, Oliveira M, Barrios C, O'Shaughnessy J, Isakoff SJ, Saji S, Freitas-Junior R, Philco M, Bondarenko I, Lian Q, Bradley D, Hinton H, Wongchenko MJ, Reilly SJ, Turner N. Dent RA, et al. Clin Cancer Res. 2024 Oct 1;30(19):4329-4338. doi: 10.1158/1078-0432.CCR-24-0465. Clin Cancer Res. 2024. PMID: 39058425 Free PMC article. Clinical Trial.
PURPOSE: In the randomized phase II LOTUS trial, combining ipatasertib with first-line paclitaxel for triple-negative breast cancer (TNBC) improved progression-free survival (PFS), particularly in patients with PIK3CA/AKT1/PTEN-altered tumors. ...PATIENTS AND METHOD …
PURPOSE: In the randomized phase II LOTUS trial, combining ipatasertib with first-line paclitaxel for triple-negative breast cance …
Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer.
El Kaddissi A, Vernerey D, Falcoz A, Mansi L, Bazan F, Chaigneau L, Dobi E, Goujon M, Meneveau N, Paillard MJ, Selmani Z, Viot J, Molimard C, Monnien F, Woronoff AS, Curtit E, Borg C, Meynard G. El Kaddissi A, et al. Clin Breast Cancer. 2024 Oct;24(7):e622-e632.e5. doi: 10.1016/j.clbc.2024.06.006. Epub 2024 Jun 19. Clin Breast Cancer. 2024. PMID: 38972830 Free article.
CONTEXT AND AIMS: Eribulin is used in taxane and anthracycline refractory HER2-negative metastatic breast cancers (MBC). Patients treated in pivotal clinical trials achieved low survival rates, therefore, the identification of prognostic criteria for long progressio …
CONTEXT AND AIMS: Eribulin is used in taxane and anthracycline refractory HER2-negative metastatic breast cancers (MBC). Patie …
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study.
Dent R, Cortés J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Haiderali A, Jia L, Nguyen AM, Pan W, O'Shaughnessy J, Schmid P. Dent R, et al. J Natl Cancer Inst. 2024 Oct 1;116(10):1654-1663. doi: 10.1093/jnci/djae129. J Natl Cancer Inst. 2024. PMID: 38913881 Free PMC article. Clinical Trial.
BACKGROUND: In KEYNOTE-522 (NCT03036488), neoadjuvant pembrolizumab plus chemotherapy and then adjuvant pembrolizumab significantly improved pathological complete response and event-free survival vs neoadjuvant chemotherapy in early-stage triple-negative breast cancer …
BACKGROUND: In KEYNOTE-522 (NCT03036488), neoadjuvant pembrolizumab plus chemotherapy and then adjuvant pembrolizumab significantly improved …
Machine learning and biological validation identify sphingolipids as potential mediators of paclitaxel-induced neuropathy in cancer patients.
Lötsch J, Gasimli K, Malkusch S, Hahnefeld L, Angioni C, Schreiber Y, Trautmann S, Wedel S, Thomas D, Ferreiros Bouzas N, Brandts CH, Schnappauf B, Solbach C, Geisslinger G, Sisignano M. Lötsch J, et al. Elife. 2024 Sep 30;13:RP91941. doi: 10.7554/eLife.91941. Elife. 2024. PMID: 39347767 Free PMC article.
METHODS: High-resolution mass spectrometry lipidomics was applied to quantify d=255 different lipid mediators in the blood of n=31 patients drawn before and after paclitaxel therapy for breast cancer treatment. A variety of supervised statistical and machine-learnin …
METHODS: High-resolution mass spectrometry lipidomics was applied to quantify d=255 different lipid mediators in the blood of n=31 patients …
Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer.
Hirmas N, Holtschmidt J, Loibl S. Hirmas N, et al. Cancers (Basel). 2024 Sep 23;16(18):3236. doi: 10.3390/cancers16183236. Cancers (Basel). 2024. PMID: 39335206 Free PMC article. Review.
The use of neoadjuvant systemic therapy (NST) has become increasingly important in the treatment of breast cancer because of its various advantages. These include the ability to downstage tumors without compromising locoregional control and the potential to obtain v …
The use of neoadjuvant systemic therapy (NST) has become increasingly important in the treatment of breast cancer because of i …
Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention.
Perez AM, Haberland NI, Miteva M, Wikramanayake TC. Perez AM, et al. Curr Oncol. 2024 Sep 23;31(9):5709-5721. doi: 10.3390/curroncol31090423. Curr Oncol. 2024. PMID: 39330051 Free PMC article. Review.
Docetaxel is a commonly used taxane chemotherapeutic agent in the treatment of a variety of cancers, including breast cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, gastric cancer, and head and neck cancer …
Docetaxel is a commonly used taxane chemotherapeutic agent in the treatment of a variety of cancers, including breast cance …
SEPT9_i1 and Septin Dynamics in Oncogenesis and Cancer Treatment.
Jędrzejczak P, Saramowicz K, Kuś J, Barczuk J, Rozpędek-Kamińska W, Siwecka N, Galita G, Wiese W, Majsterek I. Jędrzejczak P, et al. Biomolecules. 2024 Sep 22;14(9):1194. doi: 10.3390/biom14091194. Biomolecules. 2024. PMID: 39334960 Free PMC article. Review.
Given the cytoskeleton's pivotal role in regulating mechanisms critical to cancer development, further studies of the cytoskeletal elements could yield new practical applications. ...SEPT9 constitutes a biomarker of colorectal cancer (CRC) and has been positively co …
Given the cytoskeleton's pivotal role in regulating mechanisms critical to cancer development, further studies of the cytoskeletal el …
Exosomal fragment enclosed polyamine-salt nano-complex for co-delivery of docetaxel and mir-34a exhibits higher cytotoxicity and apoptosis in breast cancer cells.
Basak M, Kulkarni M, Narisepalli S, Chitkara D, Mittal A. Basak M, et al. Sci Rep. 2024 Sep 17;14(1):21669. doi: 10.1038/s41598-024-72226-0. Sci Rep. 2024. PMID: 39289425 Free PMC article.
The final formulation Exo(PAN(34a+DTX)), loaded with 40 ng/mL DTX and 50 nM miR-34a exhibited 48.20 4.59% cytotoxicity in triple negative breast cancer (TNBC) cells, 4T1. Co-localization of CM-DiI (red fluorescence) stained exosomal fragments and FAM-siRNA (green fl …
The final formulation Exo(PAN(34a+DTX)), loaded with 40 ng/mL DTX and 50 nM miR-34a exhibited 48.20 4.59% cytotoxicity in triple negative …
Molecular mechanisms of Asparagus racemosus willd. and Withania somnifera (L.) Dunal as chemotherapeutic adjuvants for breast cancer treatment.
Prasad K, Saggam A, Guruprasad KP, Tillu G, Patwardhan B, Satyamoorthy K. Prasad K, et al. J Ethnopharmacol. 2024 Sep 15;331:118261. doi: 10.1016/j.jep.2024.118261. Epub 2024 Apr 28. J Ethnopharmacol. 2024. PMID: 38685363 Free article.
ETHNOPHARMACOLOGICAL RELEVANCE: Despite various treatment modalities, the progression and metastasis of breast cancer (BC) are grave concerns due to the alarming disease-free survival rate (DFS) and overall survival rate (OS) of affected patients. ...Paclitaxel (PTX …
ETHNOPHARMACOLOGICAL RELEVANCE: Despite various treatment modalities, the progression and metastasis of breast cancer (BC) are …
Value of CDR1-AS as a predictive and prognostic biomarker for patients with breast cancer receiving neoadjuvant chemotherapy in a prospective Chinese cohort.
Yuan C, Xu Y, Zhou L, Peng J, Sha R, Lin Y, Xu S, Ye Y, Yang F, Yan T, Dong X, Wang Y, Yin W, Lu J. Yuan C, et al. Eur J Med Res. 2024 Sep 11;29(1):454. doi: 10.1186/s40001-024-02015-y. Eur J Med Res. 2024. PMID: 39261936 Free PMC article.
BACKGROUND: Neoadjuvant chemotherapy (NAC) is an effective treatment for locally advanced breast cancer (BC). However, there are no effective biomarkers for evaluating its efficacy. ...
BACKGROUND: Neoadjuvant chemotherapy (NAC) is an effective treatment for locally advanced breast cancer (BC). However, there a …
Novel Autotaxin Inhibitor ATX-1d Significantly Enhances Potency of Paclitaxel-An In Silico and In Vitro Study.
Rai P, Clark CJ, Womack CB, Dearing C, Thammathong J, Norman DD, Tigyi GJ, Sen S, Bicker K, Weissmiller AM, Banerjee S. Rai P, et al. Molecules. 2024 Sep 10;29(18):4285. doi: 10.3390/molecules29184285. Molecules. 2024. PMID: 39339280 Free PMC article.
The development of drug resistance in cancer cells poses a significant challenge for treatment, with nearly 90% of cancer-related deaths attributed to it. Over 50% of ovarian cancer patients and 30-40% of breast cancer patients exhibit resistanc …
The development of drug resistance in cancer cells poses a significant challenge for treatment, with nearly 90% of cancer-rela …
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
Matikas A, Möbus V, Greil R, Andersson A, Steger GG, Untch M, Fornander T, Malmström P, Schmatloch S, Johansson H, Hellström M, Brandberg Y, Gnant M, Loibl S, Foukakis T, Bergh J; SweBCG, ABCSG and GBG. Matikas A, et al. J Clin Oncol. 2024 Sep 10;42(26):3077-3082. doi: 10.1200/JCO.24.00178. Epub 2024 Jul 17. J Clin Oncol. 2024. PMID: 39018515 Free PMC article. Clinical Trial.
Compared with standard adjuvant chemotherapy, dose-dense treatment improved breast cancer recurrence-free survival (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.98]; P = .030), event-free survival (HR, 0.78 [95% CI, 0.65 to 0.94]; P = .009), and distant disease-free s …
Compared with standard adjuvant chemotherapy, dose-dense treatment improved breast cancer recurrence-free survival (hazard rat …
Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget's disease (EMPD-HER2DOC).
Hirai I, Tanese K, Nakamura Y, Fukuda K, Ouchi T, Hayashida T, Kameyama K, Abe T, Amagai M, Funakoshi T. Hirai I, et al. Oncologist. 2024 Sep 6;29(9):e1201-e1208. doi: 10.1093/oncolo/oyae097. Oncologist. 2024. PMID: 38823035 Free PMC article. Clinical Trial.
However, the immunohistochemical profile of EMPD reportedly resembles that of breast cancer, particularly in terms of human epidermal growth factor receptor 2 (HER2) expression, suggesting that HER2 is a promising therapeutic target for advanced HER2-positive EMPD. …
However, the immunohistochemical profile of EMPD reportedly resembles that of breast cancer, particularly in terms of human ep …
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.
Rugo HS, Schmid P, Tolaney SM, Dalenc F, Marmé F, Shi L, Verret W, Shah A, Gharaibeh M, Bardia A, Cortes J. Rugo HS, et al. Oncologist. 2024 Sep 6;29(9):768-779. doi: 10.1093/oncolo/oyae088. Oncologist. 2024. PMID: 38748596 Free PMC article. Clinical Trial.
BACKGROUND: The TROPiCS-02 study (NCT03901339) demonstrated that sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physician's choice (TPC) chemotherapy in patients with hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HE …
BACKGROUND: The TROPiCS-02 study (NCT03901339) demonstrated that sacituzumab govitecan (SG) has superior clinical outcomes over treatment of …
Oncological outcomes in patients with residual triple-negative breast cancer after preoperative chemotherapy.
Park H, Kim H, Park W, Cho WK, Kim N, Kim TG, Im YH, Ahn JS, Park YH, Kim JY, Nam SJ, Kim SW, Lee JE, Yu J, Chae BJ, Lee SK, Ryu JM. Park H, et al. Radiat Oncol J. 2024 Sep;42(3):210-217. doi: 10.3857/roj.2024.00087. Epub 2024 Sep 20. Radiat Oncol J. 2024. PMID: 39354824 Free PMC article.
PURPOSE: This study aimed to evaluate the clinical outcomes and prognostic implications of regional nodal irradiation (RNI) after neoadjuvant chemotherapy (NAC) in patients with residual triple-negative breast cancer (TNBC). MATERIALS AND METHODS: We analyzed 152 pa …
PURPOSE: This study aimed to evaluate the clinical outcomes and prognostic implications of regional nodal irradiation (RNI) after neoadjuvan …
QL1701 (a proposed trastuzumab biosimilar) versus reference trastuzumab plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer: a multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial.
Zhang QY, Cai RG, Song GH, Li CJ, Zhang BH, Kang XY, Li HP, Xu BH; QL1701 investigators. Zhang QY, et al. ESMO Open. 2024 Sep;9(9):103682. doi: 10.1016/j.esmoop.2024.103682. Epub 2024 Sep 5. ESMO Open. 2024. PMID: 39241496 Free PMC article. Clinical Trial.
Eligible patients with histologically or cytologically diagnosed HER2-positive metastatic breast cancer were randomly assigned (1 : 1) to receive either QL1701 or reference trastuzumab in combination with docetaxel (every 3 weeks) for eight cycles as the first-line …
Eligible patients with histologically or cytologically diagnosed HER2-positive metastatic breast cancer were randomly assigned …
Impact of PEG-GCSF in Breast Cancer Patients Undergoing Chemotherapy During the COVID-19 Pandemic: Single Center Experience and Literature Review.
Yokoyama K, Yoshimoto N, Takayama S, Sakamoto M, Tomoda K, Ishikawa K, Yamashita M, Suzuki H, Hosogi R, Takahashi M, Fukuda M, Kani H. Yokoyama K, et al. In Vivo. 2024 Sep-Oct;38(5):2335-2340. doi: 10.21873/invivo.13699. In Vivo. 2024. PMID: 39187320 Free PMC article. Review.
This retrospective study aimed to analyze the association between PEG-GCSF use and COVID-19 infection and severity. PATIENTS AND METHODS: Breast cancer patients who received chemotherapy at the Nagoya Tokushukai General Hospital between October 2020 and April 2023 w …
This retrospective study aimed to analyze the association between PEG-GCSF use and COVID-19 infection and severity. PATIENTS AND METHODS: …
Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer.
Bischoff H, Espié M, Petit T. Bischoff H, et al. Curr Treat Options Oncol. 2024 Sep;25(9):1225-1237. doi: 10.1007/s11864-024-01252-x. Epub 2024 Aug 17. Curr Treat Options Oncol. 2024. PMID: 39153019 Free PMC article. Review.
Neoadjuvant chemotherapy in HER2-positive early breast cancer, particularly with taxanes and anti-HER2 therapies, emerges as a cornerstone, offering enhanced breast conservation rates and prognostic insights. ...Ultimately, advocating for a personalize …
Neoadjuvant chemotherapy in HER2-positive early breast cancer, particularly with taxanes and anti-HER2 therapies, emerg …
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer.
Iwata H, Xu B, Kim SB, Chung WP, Park YH, Kim MH, Tseng LM, Chung CF, Huang CS, Kim JH, Chiu JWY, Yamashita T, Li W, Egorov A, Nishijima S, Nakatani S, Nishiyama Y, Sugihara M, Cortés J, Im SA. Iwata H, et al. Cancer Sci. 2024 Sep;115(9):3079-3088. doi: 10.1111/cas.16234. Epub 2024 Jul 9. Cancer Sci. 2024. PMID: 38979893 Free PMC article. Clinical Trial.
The global phase 3 DESTINY-Breast03 study (ClinicalTrials.gov; NCT03529110) showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) with trastuzumab deruxtecan (T-DXd) over trastuzumab emtansine (T-DM1) …
The global phase 3 DESTINY-Breast03 study (ClinicalTrials.gov; NCT03529110) showed statistically significant and clinically meaningful impro …
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial.
Zuo W, Wang Z, Qian J, Ma X, Niu Z, Ou J, Mo Q, Sun J, Li X, Wang Q, Yao Y, Yu G, Li H, Chen D, Zhang H, Geng C, Qiao G, Zhao M, Zhang B, Kang X, Zhang J, Shao Z. Zuo W, et al. Br J Cancer. 2024 Sep;131(4):668-675. doi: 10.1038/s41416-024-02751-2. Epub 2024 Jun 21. Br J Cancer. 2024. PMID: 38906970 Free PMC article. Clinical Trial.
BACKGROUND: This randomized, parallel-controlled, double-blinded, phase III equivalence study evaluated the equivalence of a proposed pertuzumab biosimilar QL1209 to the pertuzumab (Perjeta) each with trastuzumab and docetaxel in neoadjuvant treatment of early or locally advanced …
BACKGROUND: This randomized, parallel-controlled, double-blinded, phase III equivalence study evaluated the equivalence of a proposed pertuz …
Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance.
Križić M, Popović M, Silovski T, Grbin D, Dedić Plavetić N. Križić M, et al. Drugs Real World Outcomes. 2024 Sep;11(3):413-423. doi: 10.1007/s40801-024-00438-x. Epub 2024 Jun 16. Drugs Real World Outcomes. 2024. PMID: 38879832 Free PMC article.
BACKGROUND AND OBJECTIVE: Dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab combined with taxane-based chemotherapy (Cht) has been the standard first-line treatment for HER2-positive metastatic breast cancer (mBC) f …
BACKGROUND AND OBJECTIVE: Dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab combined with tax …
Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study.
Falcón González A, Cruz Jurado J, Llabrés Valenti E, Urbano Cubero R, Álamo de la Gala MC, Martínez Guisado MA, Álvarez Ambite R, Rodríguez González CJ, Amérigo Góngora M, Rodríguez Pérez L, López Álvarez P, Sánchez Rovira P, González Flores E, Henao Carrasco F, Bayo Calero J, Valero Arbizu M, Quílez Cutillas A, Salvador Boffil J, Rubio Pérez E, Ruiz-Borrego M. Falcón González A, et al. Clin Transl Oncol. 2024 Sep;26(9):2217-2226. doi: 10.1007/s12094-024-03440-5. Epub 2024 Mar 28. Clin Transl Oncol. 2024. PMID: 38538968 Free PMC article.
PURPOSE: HER2-targeted therapies have dramatically improved outcomes of patients with HER2-positive breast cancer (BC), as demonstrated in neoadjuvant trials. This study aims to provide real-world evidence on the use and effectiveness of combined pertuzumab, trastuz …
PURPOSE: HER2-targeted therapies have dramatically improved outcomes of patients with HER2-positive breast cancer (BC), as dem …
Hypoxia-induced epigenetic regulation of breast cancer progression and the tumour microenvironment.
Capatina AL, Malcolm JR, Stenning J, Moore RL, Bridge KS, Brackenbury WJ, Holding AN. Capatina AL, et al. Front Cell Dev Biol. 2024 Aug 30;12:1421629. doi: 10.3389/fcell.2024.1421629. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39282472 Free PMC article. Review.
The events that control breast cancer progression and metastasis are complex and intertwined. Hypoxia plays a key role both in oncogenic transformation and in fueling the metastatic potential of breast cancer cells. Here we review the impact of hypoxia …
The events that control breast cancer progression and metastasis are complex and intertwined. Hypoxia plays a key role both in …
Electroacupuncture facilitates vascular normalization by inhibiting Glyoxalase1 in endothelial cells to attenuate glycolysis and angiogenesis in triple-negative breast cancer.
Wan YX, Qi XW, Lian YY, Liu ZY, Wang H, Qiu YQ, Zhang CG, Li WN, Jiang HL, Yang DH, Zhao W, Chen ZS, Huang JC. Wan YX, et al. Cancer Lett. 2024 Aug 28;598:217094. doi: 10.1016/j.canlet.2024.217094. Epub 2024 Jun 29. Cancer Lett. 2024. PMID: 38945204 Free article.
Recent therapeutic strategies for the treatment of triple-negative breast cancer (TNBC) have shifted the focus from vascular growth factors to endothelial cell metabolism. ...Our study showed that peri-tumoral electroacupuncture effectively reduced the density of mi …
Recent therapeutic strategies for the treatment of triple-negative breast cancer (TNBC) have shifted the focus from vascular g …
Co-Delivery of Docetaxel and Curcumin Functionalized Mixed Micelles for the Treatment of Drug-Resistant Breast Cancer by Oral Administration.
Dian C, Qian Z, Ran M, Yan X, Dian L. Dian C, et al. Int J Nanomedicine. 2024 Aug 22;19:8603-8620. doi: 10.2147/IJN.S472445. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39188859 Free PMC article.
METHODS AND RESULTS: The study intended to develop mixed micelles using D-alpha-Tocopherol poly(ethylene glycol) 1000 succinate (TPGS) and soluplus for the co-encapsulation of docetaxel (DTX) and curcumin (CUR), marked as (DTX+CUR)-loaded mixed micelles, treating drug-resistant …
METHODS AND RESULTS: The study intended to develop mixed micelles using D-alpha-Tocopherol poly(ethylene glycol) 1000 succinate (TPGS) and s …
Thiostrepton induces spindle abnormalities and enhances Taxol cytotoxicity in MDA-MB-231 cells.
Kuo HH, Yao JS, Yih LH. Kuo HH, et al. Mol Biol Rep. 2024 Aug 21;51(1):927. doi: 10.1007/s11033-024-09863-1. Mol Biol Rep. 2024. PMID: 39168955 Free PMC article.
METHODS AND RESULTS: Immunofluorescence staining of mitotic spindles and flow cytometry analysis revealed that TST induces mitotic spindle abnormalities, mitotic arrest, and apoptotic cell death in the MDA-MB-231 triple-negative breast cancer cell line. Interestingl …
METHODS AND RESULTS: Immunofluorescence staining of mitotic spindles and flow cytometry analysis revealed that TST induces mitotic spindle a …
De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China.
Wu S, Bian L, Wang H, Zhang S, Wang T, Yu Z, Li J, Li F, Wang K, Jiang Z. Wu S, et al. World J Surg Oncol. 2024 Aug 21;22(1):214. doi: 10.1186/s12957-024-03468-5. World J Surg Oncol. 2024. PMID: 39164763 Free PMC article.
BACKGROUND: TCbHP (taxane + carboplatin + trastuzumab + pertuzumab) is the preferred neoadjuvant therapy regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. ...METHODS: This multicenter real-world study included patients with H …
BACKGROUND: TCbHP (taxane + carboplatin + trastuzumab + pertuzumab) is the preferred neoadjuvant therapy regimen for human epidermal …
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.
Opdam M, van Rossum AGJ, Hoogstraat M, Bounova G, Horlings HM, van Werkhoven E, Mandjes IAM, van Leeuwen-Stok AE, Canisius S, van Tinteren H, Imholz ALT, Portielje JEA, Bos MEMM, Bakker S, Wesseling J, Kester L, van Rheenen J, Rutgers EJ, de Menezes RX, Wessels LFA, Kok M, Oosterkamp HM, Linn SC; MATADOR trialists’ group for the Dutch Breast Cancer Research Group (BOOG). Opdam M, et al. iScience. 2024 Jun 29;27(8):110425. doi: 10.1016/j.isci.2024.110425. eCollection 2024 Aug 16. iScience. 2024. PMID: 39206149 Free PMC article.
The primary objective of the prospective, randomized, multicenter, phase 3 biomarker Microarray Analysis in breast cancer to Taylor Adjuvant Drugs Or Regimens trial (MATADOR: ISRCTN61893718) is to generate a gene expression profile that can predict benefit from eith …
The primary objective of the prospective, randomized, multicenter, phase 3 biomarker Microarray Analysis in breast cancer to T …
FTY720/Fingolimod mitigates paclitaxel-induced Sparcl1-driven neuropathic pain and breast cancer progression.
Singh SK, Weigel C, Brown RDR, Green CD, Tuck C, Salvemini D, Spiegel S. Singh SK, et al. FASEB J. 2024 Aug 15;38(15):e23872. doi: 10.1096/fj.202401277R. FASEB J. 2024. PMID: 39126272 Free PMC article.
Paclitaxel is among the most active chemotherapy drugs for the aggressive triple negative breast cancer (TNBC). Unfortunately, it often induces painful peripheral neuropathy (CIPN), a major debilitating side effect. ...Furthermore, in this TNBC mouse model that mimi …
Paclitaxel is among the most active chemotherapy drugs for the aggressive triple negative breast cancer (TNBC). Unfortunately, …
The Clinical Features and Outcomes of Pseudocirrhosis in Breast Cancer.
Phillips E, Sethi M, Vasanthakumar S, Sherpa G, Johnston S, Parton M, Kipps E, Turner NC, Foxton M, Okines A. Phillips E, et al. Cancers (Basel). 2024 Aug 12;16(16):2822. doi: 10.3390/cancers16162822. Cancers (Basel). 2024. PMID: 39199595 Free PMC article.
In total, 170 patients with a diagnosis of breast cancer and pseudocirrhosis in a 10-year period were identified and retrospectively analysed. ...In total, 89.4% of patients received chemotherapy between their diagnosis of breast cancer liver metastase …
In total, 170 patients with a diagnosis of breast cancer and pseudocirrhosis in a 10-year period were identified and retrospec …
iRGD-Guided Silica/Gold Nanoparticles for Efficient Tumor-Targeting and Enhancing Antitumor Efficacy Against Breast Cancer.
Hou X, Chen Q, Fang Y, Zhang L, Huang S, Xu M, Ren Y, Shi Z, Wei Y, Li L. Hou X, et al. Int J Nanomedicine. 2024 Aug 12;19:8237-8251. doi: 10.2147/IJN.S474135. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39157735 Free PMC article.
The tumor targeting and anti-tumor efficacy of SAIP@NPs were assessed utilizing a small animal in vivo imaging system and an in situ nude mice breast cancer xenograft model, respectively. RESULTS: The prepared SAIP@NPs exhibited decent stability and a certain slow-r …
The tumor targeting and anti-tumor efficacy of SAIP@NPs were assessed utilizing a small animal in vivo imaging system and an in situ nude mi …
ZnO-Graphene Oxide Nanocomposite for Paclitaxel Delivery and Enhanced Toxicity in Breast Cancer Cells.
Madeo LF, Schirmer C, Cirillo G, Asha AN, Ghunaim R, Froeschke S, Wolf D, Curcio M, Tucci P, Iemma F, Büchner B, Hampel S, Mertig M. Madeo LF, et al. Molecules. 2024 Aug 9;29(16):3770. doi: 10.3390/molecules29163770. Molecules. 2024. PMID: 39202850 Free PMC article.
The capacity of Z-G to enhance the toxicity of the anticancer drug Paclitaxel towards breast cancer cells was assessed via a cell viability study, showing the remarkable anticancer activity of the obtained system. ...
The capacity of Z-G to enhance the toxicity of the anticancer drug Paclitaxel towards breast cancer cells was assessed via a c …
Blood biomarkers for neuroaxonal injury and astrocytic activation in chemotherapy-induced peripheral neuropathy.
Adra J, Giglio D, Karlsson P, Zetterberg H, Einbeigi Z. Adra J, et al. Acta Oncol. 2024 Aug 5;63:636-641. doi: 10.2340/1651-226X.2024.39895. Acta Oncol. 2024. PMID: 39099324 Free PMC article.
BACKGROUND AND PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a troublesome side effect in patients exposed to taxanes in the treatment of cancer and may affect quality of life dramatically. Here we assessed whether serum levels of neurofilament light …
BACKGROUND AND PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a troublesome side effect in patients exposed to taxanes …
Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study.
Püsküllüoğlu M, Konieczna A, Świderska K, Streb J, Pieniążek M, Grela-Wojewoda A, Pacholczak-Madej R, Mucha-Małecka A, Mituś JW, Szpor J, Kunkiel M, Rudzińska A, Jarząb M, Ziobro M. Püsküllüoğlu M, et al. Acta Oncol. 2024 Aug 4;63:620-635. doi: 10.2340/1651-226X.2024.40413. Acta Oncol. 2024. PMID: 39099323 Free PMC article.
The majority of patients presented with stage II (46%) and triple-negative breast cancer (TNBC) (84%). Radiotherapy was administered to 61% of patients. Surgical procedures included breast-conserving surgery in 31% of patients and mastectomy in 68%. ...Tax …
The majority of patients presented with stage II (46%) and triple-negative breast cancer (TNBC) (84%). Radiotherapy was admini …
The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer-A Systematic Review and Meta-Analysis.
Giffoni de Mello Morais Mata D, Rush MB, Smith-Uffen M, Younus J, Lohmann AE, Trudeau M, Morgan RL. Giffoni de Mello Morais Mata D, et al. Curr Oncol. 2024 Aug 3;31(8):4486-4506. doi: 10.3390/curroncol31080335. Curr Oncol. 2024. PMID: 39195318 Free PMC article. Review.
BACKGROUND: Anthracycline-taxane is the standard chemotherapy strategy for treating high-risk early breast cancer despite the potentially life-threatening adverse events caused by anthracyclines. ...However, the efficacy of TC compared to anthracycline-tax …
BACKGROUND: Anthracycline-taxane is the standard chemotherapy strategy for treating high-risk early breast cancer despi …
Relaxation training via tele-rehabilitation program in patients with breast cancer receiving chemotherapy during COVID-19.
Bahçaci U, Uysal SA, Namal E. Bahçaci U, et al. Digit Health. 2024 Aug 2;10:20552076241261909. doi: 10.1177/20552076241261909. eCollection 2024 Jan-Dec. Digit Health. 2024. PMID: 39610824 Free PMC article.
INTRODUCTION: The COVID-19 pandemic has highlighted the significance of tele-rehabilitation in granting access to physical therapy for breast cancer patients. To mitigate the adverse effects of chemotherapy, Jacobson's relaxation techniques can be performed from the …
INTRODUCTION: The COVID-19 pandemic has highlighted the significance of tele-rehabilitation in granting access to physical therapy for br …
Germline BRCA1-Mutated Synchronous and Metachronous Pancreatic Acinar Cell Carcinoma With Long-Term Survival.
Kubo T, Ikeda Y, Muramatu J, Ishikawa K, Yoshida M, Kukita K, Imamura M, Sugita S, Sakurai A, Takada K. Kubo T, et al. Cancer Rep (Hoboken). 2024 Aug;7(8):e70007. doi: 10.1002/cnr2.70007. Cancer Rep (Hoboken). 2024. PMID: 39188100 Free PMC article.
Recently, molecular analysis revealed that PACC shows a high frequency of the BRCA1/2 mutation and is likely to be considered a cancer associated with hereditary breast and ovarian cancer (HBOC). Hereditary cancers, including HBOC, are characterized by multif …
Recently, molecular analysis revealed that PACC shows a high frequency of the BRCA1/2 mutation and is likely to be considered a cancer …
Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial.
Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, Villman KK, Halonen P, Granstam-Björneklett H, Tanner M, Sailas L, Turpeenniemi-Hujanen T, Yachnin J, Huttunen T, Neven P, Canney P, Harvey VJ, Kellokumpu-Lehtinen PL, Lindman H. Joensuu H, et al. JAMA Netw Open. 2024 Aug 1;7(8):e2429772. doi: 10.1001/jamanetworkopen.2024.29772. JAMA Netw Open. 2024. PMID: 39186271 Free article. Clinical Trial.
IMPORTANCE: The standard adjuvant treatment for patients with ERRB2-positive breast cancer is chemotherapy plus 1 year of trastuzumab. Shorter durations of trastuzumab administration improve cardiac safety, but more information is needed about their effect on surviv …
IMPORTANCE: The standard adjuvant treatment for patients with ERRB2-positive breast cancer is chemotherapy plus 1 year of tras …
Bazedoxifene Inhibits Cell Viability, Colony-Forming Activity, and Cell Migration in Human Non-Small Cell Lung Cancer Cells and Improves the Treatment Efficacy of Paclitaxel and Gemcitabine.
Huang Y, Lin J, Fu X, Li L, Fu S. Huang Y, et al. Clin Respir J. 2024 Aug;18(8):e13822. doi: 10.1111/crj.13822. Clin Respir J. 2024. PMID: 39152779 Free PMC article.
Considering that the IL6/IL6R/GP130 signaling pathway is important in tumorigenesis and metastasis, bazedoxifene is thought to have an antitumor effect, which has been proven preliminarily in breast cancer and pancreatic cancer but has not yet been studied in …
Considering that the IL6/IL6R/GP130 signaling pathway is important in tumorigenesis and metastasis, bazedoxifene is thought to have an antit …
Statins inhibit paclitaxel-induced PD-L1 expression and increase CD8+ T cytotoxicity for better prognosis in breast cancer.
Li L, Wang H, Zhang S, Gao S, Lu X, Pan Y, Tang W, Huang R, Qiao K, Ning S. Li L, et al. Int J Surg. 2024 Aug 1;110(8):4716-4726. doi: 10.1097/JS9.0000000000001582. Int J Surg. 2024. PMID: 39143707 Free PMC article.
Statin use may be potentially associated with a reduced risk of breast cancer. OBJECTIVE: To explore the relationship between statin use and cancer risk. ...RESULTS: Data from about 3.8 million cancer patients and ~1.3 million LDL-measuring individuals …
Statin use may be potentially associated with a reduced risk of breast cancer. OBJECTIVE: To explore the relationship between …
Inhibition of FBP1 expression by KMT5A through TWIST1 methylation is one of the mechanisms leading to chemoresistance in breast cancer.
Peng X, Ma L, Chen X, Tang F, Zong X. Peng X, et al. Oncol Rep. 2024 Aug;52(2):110. doi: 10.3892/or.2024.8769. Epub 2024 Jul 4. Oncol Rep. 2024. PMID: 38963044 Free PMC article.
The present study aimed to determine the function of KMT5A in inducing docetaxel (DTX) resistance in patients with breast carcinoma by evaluating glucose metabolism and the underlying mechanism involved. The upregulation or downregulation of KMT5A-related proteins was exam …
The present study aimed to determine the function of KMT5A in inducing docetaxel (DTX) resistance in patients with breast carcinoma b …
Tanshinone I improves TNBC chemosensitivity by suppressing late-phase autophagy through AKT/p38 MAPK signaling pathway.
Tang X, Gong J, Ren L, Wang Z, Yang B, Wang W, Wang N. Tang X, et al. Biomed Pharmacother. 2024 Aug;177:117037. doi: 10.1016/j.biopha.2024.117037. Epub 2024 Jul 2. Biomed Pharmacother. 2024. PMID: 38959602 Free article.
The findings from KEGG pathway analysis and molecular docking suggested that TAN might impact breast cancer chemoresistance primarily through the PI3K-Akt and MAPK signaling pathways. ...Overall, this study suggests that the combination of TAN with PTX could provide …
The findings from KEGG pathway analysis and molecular docking suggested that TAN might impact breast cancer chemoresistance pr …
Cropsi study: Efficacy and safety of cryotherapy and cryocompression in the prevention of chemotherapy-induced peripheral neuropathy in patients with breast and gynecological cancer-A prospective, randomized trial.
Brunner C, Emmelheinz M, Egle D, Ritter M, Leitner K, Wieser V, Albertini C, Abdel Azim S, Mutz-Dehbalaie I, Kögl J, Marth C. Brunner C, et al. Breast. 2024 Aug;76:103763. doi: 10.1016/j.breast.2024.103763. Epub 2024 Jun 26. Breast. 2024. PMID: 38941655 Free PMC article. Clinical Trial.
Eligible patients had a diagnosis of gynecological cancer and received a minimum of 3 cycles of taxane-based CT (neoadjuvant, adjuvant or palliative therapy). ...
Eligible patients had a diagnosis of gynecological cancer and received a minimum of 3 cycles of taxane-based CT (neoadjuvant, …
The features of male breast cancer in China: A real-world study.
Gao Y, Zhang M, Sun G, Ma L, Nie J, Yuan Z, Liu Z, Cao Y, Li J, Liu Q, Ye S, Chen B, Song Y, Wang K, Ren Y, Ye G, Xu L, Liu S, Chen Q, Li W, Chen X, Fu P, Wei W, Guo B, Wang H, Cai Z, Du C, Wu Z, Zha X, Huang H, Xu J, Zhang C, Shi Y, Liu T, Liu S, Jiang Z, Lin Y. Gao Y, et al. Breast. 2024 Aug;76:103762. doi: 10.1016/j.breast.2024.103762. Epub 2024 Jun 22. Breast. 2024. PMID: 38924994 Free PMC article.
BACKGROUND: Male breast cancer (MBC) is a rare disease. Although several large-scale studies have investigated MBC patients in other countries, the features of MBC patients in China have not been fully explored. ...The five-year OS rate for the population was 85.5 % …
BACKGROUND: Male breast cancer (MBC) is a rare disease. Although several large-scale studies have investigated MBC patients in …
Distal-Extremity Cryotherapy in Preventing Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel Administration in People Affected by Breast Cancer: A Systematic Review.
Ford K, Duddle M, Turner M, Paterson C. Ford K, et al. Semin Oncol Nurs. 2024 Aug;40(4):151673. doi: 10.1016/j.soncn.2024.151673. Epub 2024 Jun 24. Semin Oncol Nurs. 2024. PMID: 38918150 Free article. Review.
However, insufficient data supports the mainstay clinical use of cryotherapy in reducing chemotherapy-induced peripheral neuropathy from Paclitaxel use within the breast cancer population. Heterogeneity in study design, cryotherapy mode, and measurement tools unders …
However, insufficient data supports the mainstay clinical use of cryotherapy in reducing chemotherapy-induced peripheral neuropathy from Pac …
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
Cortés J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB, Chiu JWY, Pedrini JL, Li W, Yonemori K, Bianchini G, Loi S, Borges GS, Wang X, Bachelot T, Nakatani S, Ashfaque S, Liang Z, Egorov A, Hamilton E. Cortés J, et al. Nat Med. 2024 Aug;30(8):2208-2215. doi: 10.1038/s41591-024-03021-7. Epub 2024 Jun 2. Nat Med. 2024. PMID: 38825627 Free PMC article. Clinical Trial.
Patients with advanced HER2-positive metastatic breast cancer previously treated with taxane and trastuzumab were randomized to T-DXd (5.4 mg per kg (261 patients)) or T-DM1 (3.6 mg per kg (263 patients)). ...
Patients with advanced HER2-positive metastatic breast cancer previously treated with taxane and trastuzumab were rando …
Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221.
Chen CS, Zirpoli G, Budd GT, Barlow WE, Pusztai L, Hortobagyi GN, Albain KS, Godwin AK, Thompson A, Henry NL, Ambrosone CB, Stringer KA, Hertz DL. Chen CS, et al. Cancer Chemother Pharmacol. 2024 Aug;94(2):311-321. doi: 10.1007/s00280-024-04680-6. Epub 2024 May 30. Cancer Chemother Pharmacol. 2024. PMID: 38814343 Free PMC article. Clinical Trial.
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a treatment-limiting and debilitating neurotoxicity of many commonly used anti-cancer agents, including paclitaxel. The objective of this study was to confirm the previously found inverse association between …
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a treatment-limiting and debilitating neurotoxicity of many commonly used a …
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
Takano T, Masuda N, Ito M, Inoue K, Tanabe Y, Kawaguchi K, Yasojima H, Bando H, Nakamura R, Yamanaka T, Ishida K, Aruga T, Yanagita Y, Tokunaga E, Aogi K, Ohno S, Kasai H, Kataoka TR, Morita S, Toi M. Takano T, et al. Breast Cancer Res Treat. 2024 Aug;207(1):33-48. doi: 10.1007/s10549-024-07333-7. Epub 2024 May 20. Breast Cancer Res Treat. 2024. PMID: 38767786 Free PMC article. Clinical Trial.
Some of the study results were presented as a Mini Oral session at the ESMO Breast Cancer 2023 (Berlin, Germany, 11-13 May 2023)....
Some of the study results were presented as a Mini Oral session at the ESMO Breast Cancer 2023 (Berlin, Germany, 11-13 May 202 …
Supraclavicular Irradiation Induces Lymphedema in Breast Cancer Patients Treated with Axillary Lymph Node Dissection and Taxane-Containing Chemotherapy.
Horisawa N, Yoshimura A, Oze I, Sawaki M, Hattori M, Kotani H, Kataoka A, Ozaki Y, Nozawa K, Endo Y, Takatsuka D, Isogai A, Iwata H. Horisawa N, et al. Breast J. 2024 Jul 31;2024:3250143. doi: 10.1155/2024/3250143. eCollection 2024. Breast J. 2024. PMID: 39742367 Free PMC article.
PURPOSE: Breast cancer-related lymphedema (LE) significantly impairs the patients' quality of life. Axillary lymph node dissection (ALND) is a strong risk factor for LE in breast cancer surgery. In addition, postoperative administration of docetaxel (D …
PURPOSE: Breast cancer-related lymphedema (LE) significantly impairs the patients' quality of life. Axillary lymph node dissec …
Targeting DKK1 enhances the antitumor activity of paclitaxel and alleviates chemotherapy-induced peripheral neuropathy in breast cancer.
Shi HX, Tao HT, He JJ, Zhu FY, Xie CQ, Cheng YN, Hou LL, Sun H, Qin CJ, Fang D, Xie SQ. Shi HX, et al. Mol Cancer. 2024 Jul 31;23(1):152. doi: 10.1186/s12943-024-02067-y. Mol Cancer. 2024. PMID: 39085861 Free PMC article.
Therefore, there was an urgent need for a novel target to enhance the antitumor activity of paclitaxel and alleviate chemotherapy-induced peripheral neuropathy in breast cancer. Here, we found that Dickkopf-1 (DKK1) expression was upregulated in multiply subtypes of …
Therefore, there was an urgent need for a novel target to enhance the antitumor activity of paclitaxel and alleviate chemotherapy-induced pe …
Oxycodone enhances antitumor effect of paclitaxel on human breast cancer SKBR3 cells in vitro.
Liu F, Yuan H, Xu C, Mao M, Feng S. Liu F, et al. Clinics (Sao Paulo). 2024 Jul 30;79:100458. doi: 10.1016/j.clinsp.2024.100458. eCollection 2024. Clinics (Sao Paulo). 2024. PMID: 39084065 Free PMC article.
BACKGROUND: The influences of Oxycodone (OXY) combined with Paclitaxel (PTX) on breast cancer cells are unclear. The present study aimed to examine the effects of OXY combined with PTX on the proliferation, apoptosis, and migration of human breast cancer …
BACKGROUND: The influences of Oxycodone (OXY) combined with Paclitaxel (PTX) on breast cancer cells are unclear. The present s …
The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study.
Hu ZY, Liu B, Xie N, Yang X, Liu L, Xiao H, Li J, Wu H, Gao J, Lu J, Hu X, Cao M, Shui Z, Tian C, Ouyang Q. Hu ZY, et al. BMC Cancer. 2024 Jul 30;24(1):915. doi: 10.1186/s12885-024-12665-0. BMC Cancer. 2024. PMID: 39080554 Free PMC article.
AIMS: This investigation aims to elucidate the treatment status of advanced HR+/HER2- breast cancer patients in Hunan Province of Central Southern China from November 2021 to December 2022. METHODS: Data from 301 patients with advanced HR+/HER2- breast can …
AIMS: This investigation aims to elucidate the treatment status of advanced HR+/HER2- breast cancer patients in Hunan Province …
5,489 results